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ABSTRACT
MACHINE LEARNING METHODS TO IDENTIFY HIDDEN PHENOTYPES IN
THE ELECTRONIC HEALTH RECORD
Brett Kreigh Beaulieu-Jones
Jason H. Moore
Casey S. Greene

The widespread adoption of Electronic Health Records (EHRs) means an
unprecedented amount of patient treatment and outcome data is available to researchers.
Research is a tertiary priority in the EHR, where the priorities are patient care and billing.
Because of this, the data is not standardized or formatted in a manner easily adapted to
machine learning approaches. Data may be missing for a large variety of reasons ranging
from individual input styles to differences in clinical decision making, for example,
which lab tests to issue. Few patients are annotated at a research quality, limiting sample
size and presenting a moving gold standard. Patient progression over time is key to
understanding many diseases but many machine learning algorithms require a snapshot,
at a single time point, to create a usable vector form. In this dissertation, we develop new
machine learning methods and computational workflows to extract hidden phenotypes
from the Electronic Health Record (EHR). In Part 1, we use a semi-supervised deep
learning approach to compensate for the low number of research quality labels present in
the EHR. In Part 2, we examine and provide recommendations for characterizing and
managing the large amount of missing data inherent to EHR data. In Part 3, we present an
adversarial approach to generate synthetic data that closely resembles the original data
while protecting subject privacy. We also introduce a workflow to enable reproducible
vi

research even when data cannot be shared. In Part 4, we introduce a novel strategy to first
extract sequential data from the EHR and then demonstrate the ability to model these
sequences with deep learning.
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Chapter 1.  

An introduction to extracting phenotypes using machine learning in
the Electronic Health Record.

Portions of this chapter were adapted from: Beaulieu-Jones, Brett K. “Machine
Learning for Structured Clinical Data.” To appear in Advances in Biomedical Informatics
(Book Editors: Dawn Holmes and Lakhmi Jain), Springer. Preprint:
https://arxiv.org/abs/1707.06997

  Motivation for using machine learning on the structured Electronic
Health Record
Precision medicine has the potential to substantially change the way patients are
treated in many facets of health care. Precision medicine is the idea of delivering
personalized treatment and prevention strategies by considering the holistic patient,
including their genetics, environment, and lifestyle. Machine learning using structured
clinical data will likely play a large role in the success or failure of precision medicine.
Specifically, machine learning using structure data can help in finding associations
between a patient’s genotype and phenotype, identifying similar patients and evaluating
and predicting the efficacy of different clinical treatment strategies on a personalized
level.
The amount of data collected in the clinic has rapidly expanded, the first EHRs are
now more than 20 years old and the United States federal government mandated
meaningful use of EHRs by 2014. According to the American Hospital Association, by

1

2015, 96% of acute care hospitals had implemented a certified EHR. Correspondingly,
several top research institutions across the country have established departments or
institutes in biomedical informatics using the EHR as a major data source in the past 5
years.
Smartphones, wearable devices and in-clinic diagnostic tools offer the ability to
stream accurate measurements in real time. AliveCor received FDA approval in 2012 for
its iPhone-based heart monitor using machine learning to detect Atrial Fibrillation in
seconds. Billions of dollars in venture capital are currently being invested in companies,
such as Grail, Foundation Medicine, and Guardant health, promising less invasive
biopsies, or liquid biopsies, using machine learning to classify patients from circulating
tumor cells in the bloodstream. Preventative wellness clinics, such as Forward, are
emerging to characterize and track what it means to be healthy.
These are only a few examples of the many opportunities centered on patient data.
Data for both evidence-based clinical decision making and computational research is
becoming increasingly available and we must now develop new methods to preprocess
and analyze this data at a matching rate.

  Common Uses of Machine Learning for Structured Clinical Data
Each time a patient interacts with a health system, actions, notes, and measurements
are recorded in the EHR. This wealth of data has made the EHR the primary source of
structure clinical data. Three promising research applications of EHR data are:
1.) Patient clustering and disease stratification.
2.) Electronic phenotyping for genetic studies.
3.) Advising clinical treatment strategies.

2

These tasks can be performed using machine learning, but each task requires careful
preprocessing of data and appropriate phrasing of the problem to utilize traditional
machine learning methods. The nature of EHR data places emphasis on unsupervised
clustering and semi-supervised classification. In this section, we discuss these common
tasks and show examples where researchers have utilized machine learning effectively to
guide discovery. There exist many great resources for understanding machine learning
approaches as applied to general problems (1). We concentrate on how to position
relevant clinical questions and the challenges specific to the EHR that need to be solved
in order to apply these powerful techniques.
1.2.1.   Patient Clustering and Disease Stratification
As we learn more about the mechanisms and etiology of a disease, our diagnoses can
become more precise, leading to the creation of disease subtypes. Historically, cancers
were diagnosed based on their occurrence location and their reaction to different
treatments. As the mechanisms of cancer are better understood, they are further
categorized by their physiological nature. The progression of subtypes in lung cancer
illustrates the increases in resolution over time for a previously poorly defined disease
(2). Beginning with a single diagnosis based on occurrence in the lung, it was later
differentiated as small cell lung cancer and non-small cell lung cancer (3, 4). Non-small
cell lung cancer was then broken up into squamous cell carcinoma, adenocarcinoma, and
large cell carcinoma. Today these subtypes continue to be broken up based on the genetic
locations and pathways of associated risk variants.
What happens when physiological differences cannot easily be used to subtype
disease? This is true with several metabolic disorders, for example, metabolic syndrome
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has been redefined numerous times. It is associated with a wide range of comorbidities
and presents in a clinically heterogeneous manner. These comorbidities, including
coronary heart disease, diabetes, and stroke, represent an oversized risk to public health
and increasingly unwieldy burden on the health care system. Despite this, metabolic
syndrome’s predictive value for cardiovascular events, disease prediction and progression
is disputed and may not outperform the individual components that define it (5). While
the concept of identifying patients at high risk of developing diseases such as heart
disease and diabetes for early intervention is an important one, metabolic syndrome in its
current form fails to do this effectively.
Li et al. demonstrated the ability to identify disease subtypes of patients with a
metabolic disorder, type 2 diabetes (6). To do this they performed a topological analysis
of 11,210 patients with type 2 diabetes at Mount Sinai Medical Center in New York. This
topological analysis constructed a network of patients by connecting those most similar to
each other. Using this they found three unique subtypes. Subtype 1 demonstrated the
traditional observations of type 2 diabetes, hyperglycemia, obesity, and eye and kidney
diseases. Subtype 2’s main comorbidity was cancer, and subtype 3’s unique
comorbidities were neurological diseases. These subtypes are likely enriched for
etiological differences; the disease likely operates differently in someone who develops
cancer than someone who develops kidney disease. By developing a machine learning
classifier to identify which subtype a patient is in as early as possible, clinicians may be
able personalize treatment to reduce the odds of developing these more serious
comorbidities.
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Multiple sclerosis illustrates an area machine learning for disease stratification could
be particularly useful. Multiple sclerosis was traditionally subtyped into RelapsingRemitting MS and Progressive MS. In 2014, it was recommended that these subtypes be
further divided into six total subtypes (7). Unfortunately, the current strategies for
determining subtype and thus treatment strategy require looking at the progression of the
disease. This is essentially a retrospective diagnosis and means personalized treatment
plans cannot be started until progression has been observed. Could unsupervised
clustering be used to identify subtypes earlier on?
1.2.2.   Electronic phenotypes for Genetic Associations
Genetic associations examine whether a genetic variant is associated with a specific
trait. This specific trait, a phenotype, can be a moving target when dealing with the
complexity of human disease. The trait is often a human defined disease. Those with the
disease are labeled the case and those without the disease are considered controls. Early
genetic associations using the electronic health record were performed with raw
International Classification of Diseases (ICD) codes. ICD codes are recorded by
physicians when diagnosing a patient with a condition, and are used to ensure proper
billing and insurance reimbursement. ICD codes are published and updated by the World
Health Organization and are primarily used for clinical billing purposes. Despite ICD-10
being initially published in 1994, ICD-9 codes are still commonly used in both clinical
and research settings.
While ICD codes provide a clear, discrete endpoint for genetic associations, the use
of billing codes can introduce unintentional biases to analyses. An ICD code may be
added to an EHR in order to issue and receive insurance reimbursement for a test to
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screen for the disease the ICD code represents. In this case, not only is the timing of
diagnosis difficult to determine, but solely looking at the ICD codes for a patient is likely
to introduce false positives. In addition, certain ICD codes are more easily reimbursed
than others. When a clinician determines that a patient requires a treatment or test to
increase their odds of a successful outcome, the clinician is incentivized to choose the
ICD code most likely to allow them to effectively treat their patient.
Phenotype algorithms can be developed using the structured EHR to leverage both
ICD codes and the rest of the of a patient’s record. The eMERGE project is a national
network which has deployed phenotype algorithms for over 40 diseases, over 500,000
EHRs and 55,000 patients with genetic data. Many of the phenotype algorithms are
simple rules-based systems, for example: Type 2 Diabetes (Figure 1.1).
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Family history
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Figure 1.1: Phenotype Algorithms for Type 2 Diabetes Mellitus.
A.) Case selection from the EHR. B.) Control Selection from the EHR. Adapted from: (8).

An approach to study phenotype-genotype associations from the EHR are Phenomewide association studies or PheWAS (8). PheWAS use EHRs to define a phenome that
can be linked back to individual genetic variants. The approach can discover gene-disease
associations while identifying pleiotropic effects of individual SNPs. PheWAS generally
uses the ICD9 codes to construct a phenotype. While primarily used for billing, these
codes provide a set of discrete variables that can represent many phenotypes for a patient
at the same time, providing greater resolution. Besides the repurposing of billing codes, a
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major challenge of PheWAS is in understanding the functional mechanisms at work
behind GWAS SNP matches. Stratification by the 4,841 different codes creates wide
data, presenting statistical challenges in achieving adequate power. This challenge of
achieving adequate power will be exacerbated by the transition to ICD10, with less
historical data built up and the potential for over 16,000 codes. Continuing to increase
open data access will allow researchers to utilize a more accurate phenotypic
representation while lessening the burden of statistical challenges. Coding systems,
unlike patient notes or genomic data should be easier to anonymize, aggregate, and
distribute.
ICD billing codes can be biased, as evidenced by phenotype algorithms having
multiple steps to catch errors for both case and control status, using billing codes alone
may cause misclassification of phenotypes. The misclassification of phenotypes
substantially reduces the power to detect linkage in case-control studies. With 1%
phenotypic misclassification up to 10% of the power is lost, and with 5% phenotypic
misclassification, the power is reduced by approximately two-thirds (9–11).
Misclassification can occur for a variety of reasons including misdiagnosis/clinical error,
clerical error, or lack of scientific knowledge about the disease in question.
Labbe et al. showed increased linkage by clustering lifetime symptoms in
schizophrenia and bipolar disease to form more homogenous phenotypes. Separating
cases by the symptoms of psychiatric diseases compensates for the inability to subtype
these diseases by physical properties (12). This is important due to the deficit of
physiological understanding for these diseases. Labbe et al. also included familial
information to understand the heritability of these diseases. When looking at subtypes
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that show a strong familial aggregation they observed higher linkage scores. By looking
at ancestral histories for subtypes, the expected heritability could be better estimated
resulting in a reduction of “missing heritability.”
Phenotypic subtyping was also used successfully in the analysis of genetic variants
responsible for the severe development regression and stereotypical hand movements of
Rett syndrome. Causal mutations were found in the FOXG1 and MECP2 genes and
deletions at the 22q11.2 locus (13).
Each of these examples point towards the promise of using machine learning to
cluster patients based on their EHRs to identify disease subtypes or more homogenous
groups of patients for use in association studies.
1.2.3.   Clinical Recommendations
The availability of data and advances in biomedical informatics have helped to make
medicine increasingly evidence based and in some cases entirely data driven. Clinicians
and researchers now have the ability to leverage millions of data points when designing
and determining treatment best practices. The New England Journal of Medicine recently
held the SPRINT data analysis to “use the data underlying a recent article to identify a
novel clinical finding that advances medical science.” The original clinical trial sought to
see whether intensive management of systolic blood pressure (<120 mm Hg) was more
effective than standard management (<140 mm Hg). The original trial was stopped early
due to the success of the intensive management strategy in reducing cardiovascular
events. The data from the trial was released as a challenge where teams used machine
learning approaches (primarily rules based) to provide personalized recommendations.
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More personalized treatment strategies are a popular use of machine learning in the
EHR. This can be driven by genomics (pharmacogenomics), or simply by sub setting
patients based of attributes (race, BMI, etc.). Wiley et al. demonstrate the importance of
training an algorithm on a population similar to the application population (14). In their
case it was necessary to extract the percent African ancestry from the genome instead of
self reported race in order to improve the model fit.
Due to the inherent risk of adjusting clinical treatment strategies, many of the early
applications of machine learning in health systems have been seen in academic research
(retrospective analysis, drug development, pharmacogenomics) and for things like
resource usage. For example, how likely is a patient coming into the ER to need an ICU
bed? Increasingly machine learning methods are likely to be applied to clinical decisions
including providing prognosis information for shared decision making strategies. Deep
learning, in particular, is becoming an increasingly tool for drug discovery and
development (15).

  Challenges to Using Machine Learning on Structured Clinical Data
1.3.1.   Limited research labeled “gold-standards”
Large institutions and health care systems can have EHRs containing millions of
patients and billions of measurements. Despite the size of these data, electronic
phenotyping requires a gold standard to validate accuracy. This gold standard often
requires time consuming, manual clinician review and is thus expensive.
In addition, the selection of cases and controls can unintentionally create biases in
downstream algorithms and analyses. It is often easiest to select the most severe cases
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and the healthiest controls. In these circumstances researchers can have the greatest
confidence they are accurately selecting a true case or control. Unfortunately, this creates
a biased training set where it is difficult to differentiate between less severe cases and less
healthy controls. Figure 1.2 shows an illustration of a simulated dataset where the first
two principal components happen to represent the degree of the case phenotype. If the
most severe cases are selected, a classifier trained to distinguish between cases and
controls is unlikely to generalize well. If less severe cases are chosen, there may be issues
with mislabeled cases.

Healthy
Sick

Figure 1.2: Example of case vs. control selection.
Simulated disease severity plot where the 2 principal components stratify patients according to
severity.
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An example of another bias can be seen in the Type 2 Diabetes Mellitus algorithm,
controls must have at least 1 glucose measurement (Figure 1.1 B). For a young patient,
this means that a clinician must have had reason to suspect that the patient’s glucose
could be abnormal and thus could bias controls to patients who “look” like they are at a
high risk for developing Type 2 Diabetes.
Because patients move between health systems, a patient may not be diagnosed in
the system they are treated in and may only have a partial history. Some methods for
controlling for incomplete histories can result in smaller sample sizes. It is common to
include only patients who have a visit in the system prior to the diagnosis of the
phenotype of interest. While this can help to determine the diagnosis date for a disease, it
excludes anyone who was diagnosed on their first visit to a particular health system.
1.3.2.   Missing Data
The average patient is unlikely to have measurements for the clear majority of fields
in the EHR. It does not make sense logistically or economically to administer every test
to a seemingly healthy patient. There are three primary types of missing data:
1.)   Missing Completely at Random (MCAR) – when data is missing in a
completely unrelated way to the values of both the observed and the
unobserved data.
2.)   Missing at Random (MAR) – when the data is missing based on the observed
data, when other fields in the EHR indicate whether the value will be present
or absent.
3.)   Missing Not at Random (MNAR) – when the data is missing based on the
values of the unobserved data.
Figure 1.3 shows the ability to use a random forest to predict whether a lab value will
be present or absent based on other lab values. Unsurprisingly data that is MCAR cannot
12

be predicted (Figure 1.3 A), and data that is either MAR or MNAR (Figure 1.3 B, 1.3 C)
can be predicted with an accuracy significantly greater than random. In practice, most
missing data in the EHR tends to be of the MAR variety. Clinicians must decide which
measurements are relevant and fiscally responsible, irrelevant tests are wasteful and it
does not make sense to subject patients to unnecessary discomfort. The clinician is
making these decisions based on the observations they make, so when data is missing it is
related to the observed data.

Figure 1.3: Predicting the presence of data under different missing data mechanisms.
A.) Data that is missing completely at random cannot be predicted. B & C.) Data that is missing
at random and missing not at random can be predicted at better than random accuracy (to appear
(16)).

MCAR data is less likely to present issues to downstream analyses than data that is
either MAR or MNAR, but if not handled correctly all three types of missing data can
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introduce unintentional biases to all sorts of downstream analyses including machine
learning. Machine learning algorithms often expect a complete matrix as input and are
not designed to handle null values. This often leads to researchers performing one of
three options:
1.)   Perform feature selection of relevant features and use only complete cases, or
patients that have values for all features.
2.)   Modify the algorithm to accept null inputs (often by ignoring them) or
3.) Perform imputation to predict what the value for a feature would be.
Each of these options have several pros and cons and can have unintended effects on
machine learning. When performing complete case analysis after feature selection, the
features included can lead to including either more severe cases or cases that were harder
to diagnose. Imagine a disease that is diagnosed by a laboratory measurement where
values over 10 conclusively indicate you have the disease but values between 8 and 10
require an additional test. If the additional test is included in the features selected, the
complete cases are now only the patients that were harder to diagnose. When modifying
an algorithm to accept null inputs, the researcher needs to be careful that the algorithm
does not disproportionately learn to depend on patients that have all of the measurements
or only the most complete measurements. If the algorithm relies on patients with all of
the measurements, many of the same issues that arise in complete case analysis repeat. If
the algorithm learns to ignore rare measurements it can miss signal. For example, in an
analysis of different treatment options, say 40 of 10,000 patients suffered a fairly rare but
severe adverse event. Without careful monitoring the algorithm may not place enough
importance on this feature despite the fact this outcome is disproportionately important.
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C.

Difference between imputation runs

Difference between imputation runs

Difference between imputation runs

B.

A.

RMSE Imputed vs. Spike-in

RMSE Imputed vs. Spike-in

RMSE Imputed vs. Spike-in

Figure 1.4: Comparison between spike-in accuracy and variation between imputation runs.

Imputation can be effective in the EHR because many missing values can be inferred
by omission and just knowing whether a value was present or absent can be useful. If a
patient has never had a chest x-ray, it is unlikely that their physician suspects a broken rib
cage. This information can be provided to downstream machine learning algorithms by
performing imputation. It is, however, very important to carefully analyze the results of
imputation. Oftentimes much can be learned simply by looking at which methods are the
most accurate. Direct accuracy can be measured by spiking in missing values to replace
known values, imputing these spiked-in values and measuring their difference from the
real values. Despite this direct accuracy should only be used as a benchmark, and it is
important to analyze the effect of imputation on the downstream analyses you are
performing (Figure 1.4).
For example, mean imputation may perform strongly in an analysis using spiked-in
missingness but remove all variance from the imputed values for a feature (Figure 1.4 C).
Other evaluation criteria, such as, comparing the variance between imputed values of
different imputation runs and the difference between imputed values and real values.
Ideally these values would be highly correlated in order to maintain the variance
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structure. Popular imputation methods for EHRs include K-Nearest Neighbors, Singular
Value Decomposition and Multiple Imputation by Chained Equations.
All three of these strategies for handling missing data may introduce bias when
performing EHR-based analyses. It is important to consider potential effects and ideally
to utilize multiple strategies and examine the differences.
1.3.3.   Privacy, Reproducibility, and Data Sharing
Patient privacy needs to be a focus of any secondary use of EHRs. Because a patients
EHR is ‘de-identified’ does not mean that it is anonymous. Latanya Sweeney
demonstrated this emphatically when the Massachusetts Group Insurance Commission
released de-identified data on state employees (17). These records included each hospital
visit and Sweeney re-identified several patients including the former Governor of
Massachusetts. Sweeney did this from his birth date, zip code and sex alone, and to prove
a point mailed the Governor a copy of his personal records. The task of re-identification
has been shown possible in several other cases where data holders attempted to share
their data, including the Netflix challenge. Narayana and Shmatikov were able to deanonymize users in the Netflix challenge by linking their viewing histories with popular
movie review sites. For users who had rated more than 6 movies, they were able to do
this with greater than 90% accuracy (18). This, in part, led to Netflix canceling the
second iteration of its popular recommendation contest following a privacy lawsuit.
Caution needs to be taken even when the actual data is not released. Deep learning
models can have many millions of parameters, allowing adversaries to perform
membership inference attacks in order to determine whether a user was a member of the
study or not. Shokri et al. (19) demonstrate greater than 90% precision even with 30,000
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examples in the training set. They do this by examining the trained parameters of a deep
neural network trained on the CIFAR-100 dataset. Even without the model, enterprising
adversaries performed membership inference attacks with only black-box access to the
target model through an API. Shokri et al. again demonstrated this on various purchase
history datasets made available through Amazon and Google APIs.
One approach to adding privacy protection is called “Differential Privacy” (20).
Differential Privacy is a robust, meaningful and mathematical rigorous definition of
privacy which operates under the knowledge that data cannot be fully anonymized and
remain useful. If you remove all of the signal in a dataset to anonymize, machine learning
methods are fruitless. If you keep any signal at all, there is a chance an adversary will
able to discover information about the members of the dataset. The goal of differential
privacy is to find a balance between an acceptable risk, the privacy budget, and
usefulness of the data. It attempts to minimize the likelihood an adversary can perform a
membership inference attack to determine if a subject is in a dataset. It works by adding a
plausible deniability of any outcome by inserting random noise into the information made
available. If balanced, meaningful answers can be interrogated from the data while
greatly reducing the risk that any member of a study is harmed by de-identification. A
classic example and simple way to think about differential privacy is to imagine a study
where participants are told to answer a question. Before answering the question they flip
a coin, if the coin lands heads, they give the real answer, the truth. If the coin lands tails,
they answer randomly by flipping an additional coin and responding yes if it lands heads
and no if it lands tails.
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Simmons et al. used a variant of differential privacy to enable privacy preserving
genome wide association studies even when there is significant population stratification.
Genomic data has a high dimensionality and relatively low signal to noise ratio making
de-identification or other attempts at masking individual records impractical. They
demonstrate the ability to allow users to query summary statistics while minimizing
privacy risks. This is a particularly interesting application because while genome
sequencing prices have rapidly decreased, the combined costs of recruitment and
sequencing are a major barrier to this type of research. This method allows for increased
sharing of valuable, difficult to obtain datasets. Differential privacy is a rapidly growing
area, we suggest “The Algorithmic Foundations of Differential Privacy” (21) as a starting
point if interested in implementing differential privacy.
Privacy challenges can make sharing data prohibitively difficult. This in turn
presents challenges in reproducing work from other researchers. Even if source code is
shared, researchers attempting to reproduce original research generally can only compare
final results. This means that even if a protocol of a paper is well written and described, if
it has 100 steps, a researcher attempting to reproduce cannot be sure where their results
diverged. Because of this challenge we strongly advocate publishing intermediate results.
This can help narrow down divergences to a few steps, was it the data? The
preprocessing? The actual analysis? The plotting into charts? One way to release
intermediate results without adding a large amount of additional work is to use
continuous integration to run the analysis and export the log file (22).
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1.3.4.   Longitudinal Data
A key attribute and potential strength of EHRs is the ability to track the way a patient
progresses over time. Early moving caregivers such as Geisinger Health System
implemented initial EHRs over twenty years ago but fully utilizing this longitudinal
presents challenges to researchers.
Longitudinal EHR data are often irregular time series. Measurements are recorded at
irregular times, can be mixed type (continuous, ordinal, categorical), require feature
extraction (images, free text). It is common for researchers to take a single time point (i.e.
current time, set time after diagnosis etc.) and use this as the single end point or label for
machine learning analyses. This can be problematic when patients have arrived at that
point through very different routes. For example, if using a systolic blood pressure as an
end point, one patient may be on an intensive blood pressure management protocol while
another with the same blood pressure may have never taken medication. In the SPRINT
clinical trial there were patients on as many as seven medications to manage blood
pressure (23), if unmedicated these patients would almost definitely have significantly
higher measurements. One method researchers use to remediate this issue is to derive
statistics to represent the time series, such as taking the median value. This can be
insufficient when the way clinicians choose to observe and treat patients based on data
either not recorded in the electronic health record, in the unstructured data or in fields not
selected for inclusion can also bias the labels. For example, if patient A has a single
normal white blood cell count, and patient B has had a monthly count every month for
the past 5 years. A clinician could have been checking to see if patient A showed an
increased white blood cell count after a surgery suspecting a possible infection. In
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contrast, the repeated measurements for patient B indicate the clinician may have a
reason to believe patient B is immunocompromised or may become
immunocompromised due to a virus or adverse reaction to a medication and is using the
white blood cell count to monitor this. Despite the patients having relatively equal white
blood cell counts, using this single value as a label is clearly inadequate to represent the
complete state of the patient. For this specific case deriving a panel of statistics including
features such as the count and variance of the measurement could help to better represent
the current state of a patient. Recent work takes this further to calculate disease and
patient trajectories by generating networks of the way a patient or disease progresses over
time. Jensen et al. demonstrated this using 6.2 million patients from Danish National
Patient Registry to cluster patients based on time dependent disease diagnoses (24).
These disease diagnoses were extracted from patterns of ICD-9 codes on patient’s EHRs.
This method creates a visualization of patient trajectories and allows for analyses of comorbidities observed in health systems in order to identify important patterns that
indicate the potential for more severe outcomes. Further work in this field could move
beyond billing codes to allow for increased resolution of patient trajectories.
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Chapter 2.  

Semi-Supervised Learning of the Electronic Health Record with
limited “gold-standard” labels.

This chapter was originally published as: Beaulieu-Jones, Brett K., Casey S. Greene, and
the Pooled Resource Open-Access ALS Clinical Trials Consortium. "Semi-supervised
learning of the electronic health record for phenotype stratification." Journal of
biomedical informatics 64 (2016): 168-178. doi: 10.1016/j.jbi.2016.10.007
B.K.B.-J. and C.S.G. conceived the study and designed the solution. B.K.B.-J.
implemented and performed the analysis. B.K.B.-J. and C.S.G. wrote, revised and
approved the manuscript.
Data used in the preparation of this article were obtained from the Pooled Resource Open-Access ALS
Clinical Trials (PRO-ACT) Database. As such, the following organizations and individuals within the
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provided data, but did not participate in the analysis of the data or the writing of this report: Neurological
Clinical Research Institute, MGH, Northeast ALS Consortium, Novartis, Prize4Life, Regeneron
Pharmaceuticals, Inc., Sanofi, Teva Pharmaceutical Industries, Ltd.

  Abstract
Patient interactions with health care providers result in entries to electronic health
records (EHRs). EHRs were built for clinical and billing purposes but contain many data
points about an individual. Mining these records provides opportunities to extract
electronic phenotypes, which can be paired with genetic data to identify genes underlying
common human diseases. This task remains challenging: high quality phenotyping is
costly and requires physician review; many fields in the records are sparsely filled; and
our definitions of diseases are continuing to improve over time. Here we develop and
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evaluate a semi-supervised learning method for EHR phenotype extraction using
denoising autoencoders for phenotype stratification. By combining denoising
autoencoders with random forests we find classification improvements across multiple
simulation models and improved survival prediction in ALS clinical trial data. This is
particularly evident in cases where only a small number of patients have high quality
phenotypes, a common scenario in EHR-based research. Denoising autoencoders perform
dimensionality reduction enabling visualization and clustering for the discovery of new
subtypes of disease. This method represents a promising approach to clarify disease
subtypes and improve genotype-phenotype association studies that leverage EHRs.

  Introduction
Biomedical research often considers diseases as fixed phenotypes, but many have
evolving definitions and are difficult to classify. The electronic health record (EHR) is a
popular source for electronic phenotyping to augment traditional genetic association
studies, but there is a relative scarcity of research quality annotated patients (25).
Electronic phenotyping relies on either codes designed for billing or time intensive
manual clinician review. This is an ideal environment for semi-supervised algorithms,
performing unsupervised learning on many patients followed by supervised learning on a
smaller, annotated, subset. Denoising autoencoders (DAs) are a powerful tool to perform
unsupervised learning (26). DAs are a type of artificial neural network trained to
reconstruct an original input from an intentionally corrupted input. Through this training
they learn higher-level representations modeling the structure of the underlying data. We
sought to determine whether applying DAs to the EHR could reduce the number of
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annotated patients required, construct non-billing code based phenotypes and elucidate
disease subtypes for fine-tuned genetic association.
The United States federal government mandated meaningful use of EHRs by 2014 to
improve patient care quality, secure and communicate patient information, and clarify
patient billing (27, 28). Despite not being designed specifically for research, EHRs have
already proven an effective source of phenotypes in genetic association studies (29, 30).
Initially, phenotypes were hand designed based on manual clinician review of patient
records. These studies were limited by the time and cost inherent in manual review (31,
32), but DAs can make use of unlabeled data. After unsupervised pre-training, the trained
DA’s hidden layer can be used as input to a traditional classifier to create a semisupervised learner. This allows the DA to learn from all samples, even those without
labels, and requires only a small subset to be annotated. Today, phenome-wide
association studies (PheWAS) are the most prevalent example of EHR phenotyping,
proving particularly effective at identifying pleiotropic genetic variants (33). PheWASs
often use algorithms based on the International Classification of Disease (ICD) codes to
construct a phenotype. This coding system was designed for billing, not to capture
research phenotypes. DA constructed features are combinations of many components of
clinical data and may provide a more holistic view of a patient than billing codes alone.
Through extensive study, disease diagnoses can become more precise over time (2–
4, 34, 35). Cancers, for example, were historically typed by occurrence location and the
efficacy of different treatments. As the mechanisms of cancer are better understood, they
are further categorized by their physiological nature. The progression of subtypes in lung
cancer illustrates this increased understanding over time (34). Beginning with a single
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diagnosis based on occurrence in the lung, lung cancer has been divided into dozens of
subtypes over several decades based on histological analysis, and genetic markers (2–4,
35). The unsupervised nature of DAs means that even if the definitions of a disease
change, they would not need to be retrained. The ability to identify more homogenous
phenotypes showed increased genotype to phenotype linkage in schizophrenia, bipolar
disease (12), and Rett Syndrome (13, 36–38). Furthermore, type 2 diabetes subtypes have
been discovered using topological analysis of EHR patient similarity (6). The
dimensionality reduction possible with a DA makes clustering and visualization more
feasible. Subtyping exposes disease heterogeneity and may contribute to additional
physiological understanding.
Previous work in semi-supervised learning of the EHR relies on closed source
commercial software (6), and natural language processing of free text fields to match
clinical diagnosis (39, 40). We are not aware of any previous work performing semisupervised classification and clustering from quantitative structured patient data.

  Methods
We developed an approach, entitled “Denoising Autoencoders for Phenotype
Stratification (DAPS),” that constructs phenotypes through unsupervised learning. This
generalized phenotype construction can be used to classify whether patients have a
particular disease or to search for disease subtypes in patient populations. To evaluate
DAPS, we created a simulation framework with multiple hidden factors influencing
potentially overlapping observed variables. We evaluated the reduced DA models against
feature-complete representations with popular supervised learning algorithms. These
evaluations covered both complete datasets, as well as the more realistic cases of
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incompletely labeled and missing data. We developed a technique that uses the reduced
feature-space of the DA to visualize potential subtypes. Finally, we evaluate DAs ability
to predict ALS patient survival in both classification and clustering tasks. Each of these is
fully described below and full parameters included in sweeps are available in the
supplementary materials.
Source code to reproduce each analysis is included in our repository
(https://github.com/greenelab/DAPS) (41) and is provided under a permissive open
source license (3-clause BSD). A docker build is included with the repository to provide
a common environment to easily reproduce results without installing dependencies (42).
In addition, Shippable, a continuous integration platform, is used to reanalyze results in a
clean environment and generate figures after each commit (43).
2.3.1.   Unsupervised Training with Denoising Autoencoders
DAs were initially introduced as a component in constructing the deep networks
used in deep learning (44). Deep learning algorithms have become the dominant
performers in many domains including image recognition, speech recognition and natural
language processing (45–50). Recently they have also been used to solve biological
problems including tumor classification, predicting chromatin structure and protein
binding (26, 51, 52). DAs showed strong performance early in the deep learning
revolution but have been surpassed in most domains by convolutional neural networks or
recurrent neural networks (44). While these complex deep networks have surpassed the
performance of DAs in these areas, they rely on strictly structured relationships such as
the relative positions of pixels within an image (47, 53). This structure is unlikely to exist
in the EHR. In addition, complex deep networks are notoriously hard to interpret. DAs
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are easily generalizable, benefit from both linear and nonlinear correlation structure in the
data, and contain accessible, interpretable, internal nodes (26). Oftentimes the hidden
layer is a “bottle-neck”, a much smaller size than the input layer, in order to force the
autoencoder to learn the most important patterns in the data (53).
We used the Theano library (54, 55) to construct a DA consisting of three layers, an
input layer x, a single hidden layer y, and a reconstructed layer z (44) (Figure 2.1A).
Noise was added to the input layer through a stochastic corruption process, which masks
20% of the input values, selected at random, to zero.
The hidden layer y was calculated by multiplying the input layer by a weight vector
W, adding a bias vector b and computing the sigmoid (Formula 1). The reconstructed
layer z was similarly computed using tied weights, the transpose of W and b (Formula 2).
The cost function is the cross-entropy of the reconstruction, a measure of distance
between the reconstructed layer and the input layer (Formula 3).

𝑐𝑜𝑠𝑡 = 	
   −

𝑦 = 𝑠 𝑊𝑥 + 𝑏

(Formula 1)
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(Formula 2)
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(Formula 3)

Stochastic gradient descent was performed for 1000 training epochs, at a learning
rate of 0.1. Hidden layers of two, four, eight and sixteen hidden nodes were included in
the parameter sweep with a 20% input corruption level. Vincent et al. (44) provide a
through explanation of training for DAs without missing data.
In the event of missing data, the cost calculation was modified to exclude missing
data from contributing to the reconstruction cost. A missingness vector m was created for
each input vector, with a value of 1 where the data is present and 0 when the data is
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missing. Both the input sample x and reconstruction z were multiplied by m and the crossentropy error was divided by the sum of the m, the number of non-missing features to get
the average cost per feature present (Formula 4). This allowed the DA to learn the
structure of the data from present features rather than imputation.
𝑐𝑜𝑠𝑡 = 	
   −
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(Formula 4)
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Figure 2.1: Diagram of Denoising Autoencoder and Simulation Procedure.
A.) Network diagram of DAs used for unsupervised pre-training. Input data is intentionally
corrupted and then weights and biases are learned to minimize reconstruction cost when mapping
the data to a hidden layer and back to a reconstructed layer. B.) Supervised classification occurs
using the pre-trained DA hidden nodes as input to a traditional classifier. C.) Simulation model
with example cases and controls under each rule set.
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2.3.2.   Supervised Denoising Autoencoder Classifier
To convert the DA to a supervised classifier, we first trained the DA in an
unsupervised fashion (pre-training) (Fig 2.1 A). We then applied a variety of traditional
machine learning classifiers including, decision trees, random forests, logistic regression,
nearest neighbors and support vector machines to the pre-trained unsupervised hidden
layer values, y, of the DA (Figure 2.1 B). Random forests applied to DA hidden nodes
(DA+RF) were shown for all comparisons. Predictive performance was measured by
comparing the AUROC using stratified 10-fold cross validation. The Scikit-learn library
was used for the traditional classifiers (56). The Support Vector Machine uses a radial
basis function kernel, with a penalty parameter of 1. The nearest neighbors classifier uses
a k-value of 5 and the random forest uses 10 estimators. These parameters achieved
optimal performance in a preliminary parameter sweep.
2.3.3.   Simulation Framework
We designed four simulation models to evaluate algorithmic performance. These
simulations were not designed to perfectly recapitulate EHR data. Instead they are
designed to capture a variety of complexity in order to identify algorithmic strengths and
weaknesses with known underlying models.
To simulate patients, first clinical observations were generated by first drawing
random samples from a normal distribution. Next hidden input effects were generated in
accordance with one of four simulation models. When turned on these hidden input
effects shift 1 to N observed clinical variables with replacement (Figure 2.1 C). Shifted
clinical features were chosen at random, but consistent for all patients. Case-control
status was determined by rules applied to the hidden input effects, where 1 represents the
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effect being on and 0 represents the effect being off. Next, a confounding systematic bias
was added to a random subset (33%) of the patients as a source of additional noise to
simulate the variance accompanying data created by physicians, labs, hospitals or other
spurious effects.
There are four models defining hidden input effect rules to determine case-control
status:
1.  

All together/all relevant. Individuals have the same value (0 or 1) for all
hidden input effects. Controls have all hidden effects set to 0. Cases have all
hidden effects set to 1. A model capturing any hidden input will be able to
predict case/control status in this scenario. This is a test of whether each
method can recognize any of the hidden effects.

2.  

All independent /single effect relevant. Individuals have 0 to N (specified per
simulation) hidden input effects chosen at random. One arbitrary effect (the last
one) is used to determine case-control status. In controls, this is 0. In cases, this
is 1. A model capturing the relevant hidden input will be able to predict
case/control status in this scenario. This is a test of whether each method can
recognize the important hidden effect when there are multiple shifted
distributions.

3.  

All independent/percentage based. Individuals have 0 to N (specified per
simulation) of hidden input effects chosen at random set to 1. The percentage of
hidden input effects on represents the probability of the patient being a case. A
model capturing more hidden effects will be able to more accurately predict
case/control in this scenario. This is a test of whether each method can perform
effectively without a hard-rule based model, and could represent a disease with
incomplete penetrance.

4.  

All independent/complex rule based. Individuals have 0 to N (specified per
simulation) of hidden inputs chosen at random set to 1. The sum of hidden
effects determines case-control status (cases are even, controls are odd). A
model must capture all hidden effects to successfully predict case/control in
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this scenario. This is a test to identify the complexity limitations of each of the
methods.

Simulation model 3 could reflect a disease with incomplete penetrance. The
probabilistic manner of this simulation means that the optimum binary classifier will have
an expected accuracy limited by the role of stochasticity in the model. The amount of
stochasticity is a function of the number of hidden effects. In this model, case control
odds were equal to the percentage of hidden input effects on. If there are 4 hidden input
effects and 2 are on, the patient has a 50% chance of being a case and a 50% chance of
being a control. A binary classifier can perfectly model this simulation and still have
error due to the probabilistic nature. The maximum expected accuracy was calculated
from a binomial distribution multiplied by the minority percentage as the best a binary
classifier could do is choose the more likely class. For example, in the case of 4 hidden
effects the maximum expected accuracy is 68.75%.
An example of a hypothetical condition a hidden input effect could represent is the
familial hypercholesterolemia genotype. For a patient with the familial
hypercholesterolemia genotype, the simulated clinical observations could represent
increases in levels of total and low-density lipoprotein cholesterol, the deposition of
cholesterol in extravascular tissues, corneal arcus and elevated triglyceride levels (57).
Some factors such as elevated triglyceride levels are not solely the result of the genetic
predisposition and are related to environmental factors. Hypothetically additional hidden
input effects on the same observed variable would represent these other factors. Because
our goal is to evaluate methods for their ability to broadly capture these types of patterns,
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we generate randomized relationships between hidden and observed variables. This
avoids overfitting our evaluation to specific phenotypes.
2.3.4.   Supervised Classification Comparison
If successfully trained, the hidden layer of a DA, y, captures the first n factors of
variation in the data, where n is the number of nodes in the hidden layer. To test whether
the DA constructed useful features by learning the main factors of variation in the data
we used the trained hidden layer as an input to a shallow classifier.
To do this, we first completed unsupervised pre-training of the DA with all of the
simulated samples. The hidden layer values, y, were calculated for all samples using the
trained DA without any corruption and fed in as the features to a random forest to form a
supervised classifier.
Classification performance between DAs plus random forests (DA+RF) were
compared against decision trees, random forests, nearest neighbors and support vector
machines in a parameter sweep under each model (Table 2.1). Additional model
parameters included in sweeps are included in the supplementary materials. All
traditional classifiers were implemented with Scikit-learn (56). Classification
performance was compared using the AUROC with 10-fold cross validation across 10
independent replicates for each set of parameters.
PARAMETER

VALUES

OBSERVED VARIABLES

50, 100, 200, 400

EFFECT MAGNITUDE (X VARIANCE)

1, 2, 4

HIDDEN INPUT EFFECTS

1, 2, 4, 8, 16

EFFECTED OBSERVED VARIABLES PER

5, 10

HIDDEN
INPUT EFFECT
UNLABELED
PATIENTS

10,000
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LABELED PATIENTS

100, 200, 500, 1,000,

SYSTEMATIC BIAS

2,0000.1 applied to 0.33 of

DA HIDDEN NODES

patients
1, 2, 4, 8

Table 2.1 : Simulation Model 1 Parameter Sweep Specifications.

2.3.5.   Semi-Supervised Classification Comparison
The supervised classification comparison was repeated but with additional patients
simulated and utilized during the unsupervised pre-training of the DA. The additional
patients were simulated at the same 50% case, 50% control ratio but their labels were
discarded after simulation. These additional patients were mixed with the original labeled
patients and included in the unsupervised pre-training of the DA. The unlabeled samples
were then discarded and the DA+RF was then provided the same, labeled, patient groups
as the traditional classifiers. The labeled patient samples were run through the trained DA
in the same manner as the unsupervised pre-training but without any corruption added to
the data. The DA+RF and traditional classifiers were evaluated in a parameter sweep
under each model using 10-fold cross validation.
2.3.6.   Missing Data Comparison
The semi-supervised classification comparison was repeated five times with, 0%,
10%, 20%, 30% and 40% of the data missing. Missing data was added at random per
sample, depending on the specified percentage missing.
Throughout these trials, the cost calculation was modified to exclude missing data
from the cost and allow the DA to learn without imputing values (Formula 4). The
traditional classifiers were trained using mean imputation for missing data. Mean
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imputation is particularly well suited for the simulation models because the observations
were drawn from normal distributions, potentially giving an advantage to the non-DA
algorithms that would not be available in many real datasets.
As in the semi-supervised classification comparison trial, the DA+RF and traditional
classifiers were evaluated under each model using 10-fold cross validation.
2.3.7.   Clustering and Visualization
To interpret and visualize results, patient populations were clustered using principal
components analysis (PCA) and t-Stochastic Neighbor Embedding (t-SNE) of the trained
DA’s hidden nodes (58, 59). PCA and t-SNE were implemented with the Sci-kit learn
library (56).
Ten thousand patients (5,000 cases, 5,000 controls) with four hidden effects were
simulated under model 1. PCA followed by t-SNE was performed initially on the raw
input for comparison and then on the hidden nodes of the DA after every 10 training
epochs.
To test the ability to identify subtypes, we simulated 15,000 patients, 5,000 cases
under model 1, 5,000 cases under model 2, and 5,000 controls. Input observations were
compared to two, three and four-node DAs using PCA followed by t-SNE.
2.3.8.   ALS Survival Analysis
Data used in the ALS Survival portion of this article were obtained from the Pooled
Resource Open-Access ALS Clinical Trials (PRO-ACT) Database. In 2011, Prize4Life,
in collaboration with the Northeast ALS Consortium, and with funding from the ALS
Therapy Alliance, formed the Pooled Resource Open-Access ALS Clinical Trials (PROACT) Consortium. The data available in the PRO-ACT Database has been volunteered
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by PRO-ACT Consortium members. The PRO-ACT dataset includes 23 clinical trials
covering 10,723 patients. We limit our survival analysis to the 3,398 patients with known
death information, but perform unsupervised pre-training of the DA with all 10,723
patients.
Patient data includes quantitative features consisting of demographic information,
diagnosis history, family history, treatment history, vital sign readings, concomitant
medications and laboratory tests. Categorical variables were converted to one-hot
encoding. Repeated or temporal measurements were encoded as the mean, minimum,
maximum, count, standard deviation and slope across each repeat. Measurement scales
were standardized and input features were normalized to be between 0 and 1. No
imputation was performed on the input to the DA; K-nearest neighbors imputation
(K=15) was performed for the raw comparison. This preprocessing resulted in an input
layer of 6,812 numerical features per patient.
Patient survival was predicted as the number of days from disease onset. Random
Forest Regression using Scikit-learn with 1,000 estimators was performed on the raw
data and the hidden layer of a 250 node DA trained for 1,000 epochs. Performance was
evaluated using 10-fold cross validation. Cluster analysis using t-SNE was compared
between PCA (2, 4, 8, and 16 components) on the raw input with the hidden layer of the
DA.

  Results
2.4.1.   Case-Control DA Training Visualization
We trained a DA and visualized the training process using PCA and t-SNE. These
visualization techniques offer intuition and the ability to examine the sub-clusters. Given
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5,000 cases and 5,000 controls under simulation model 1, PCA and t-SNE alone did not
yield defined clusters (Figure 2.2 A). Figures 2.2 B-F show the separation of cases from
controls as the DA is trained. One thousand epochs of training via stochastic gradient
descent were found to be sufficient for the convergence of reconstruction cost and
stabilization of visualizations within simulated data (Figure 2.2 E and F, Supplemental
Figure 1).

Figure 2.2: Visualization of DA training over time.
Case vs. Control clustering via principal components analysis and t-distributed stochastic
neighbor embedding throughout the training of the DA. Controls are shown in yellow, cases are
shown in red. A.) Raw input B.) 0 training epochs C.) 10 training epochs D.) 100 training epochs
E.) 1,000 training epochs F.) 10,000 training epochs.

2.4.2.   Fully Supervised Comparison
To examine the ability of DAs to learn the structure of the data we compare the
predictive ability of classification algorithms applied to the DA constructed through
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unsupervised training. Random forests demonstrated a strong balance of performance and
stability, and were used for all comparisons. We then compare the DA plus a random
forest classifier (DA+RF) to the top performing classifiers on raw input data (Table 2.2).

PATIENTS DA+RF RANDOM
FOREST
100
200
500
1000
2000
MEAN

0.618
0.637
0.677
0.774
0.755
0.692

0.653
0.610
0.690
0.717
0.736
0.681

SUPPORT
VECTOR
MACHINE
0.504
0.449
0.663
0.776
0.862
0.651

DECISION
TREE

NEAREST
NEIGHBORS

0.599
0.589
0.617
0.634
0.643
0.616

0.635
0.608
0.642
0.651
0.658
0.639

Table 2.2: Mean Receiver Operating Curve Area Under Curve by method under simulation model
1. (10 Replicate, 10-fold cross validation)

Key trends emerged under each model; with few patients SVMs had AUCs
indistinguishable from those expected from a random classifier. As one would expect,
SVMs were top performers at when the number of patients was high. Random forest
classification performance scaled steadily with patient count. The DA+RF performed
similarly to the random forest, showing that a 2-node DA is able to capture at least one of
the input hidden effects. Capturing any signal is sufficient to accurately classify
simulation model 1.
2.4.3.   Semi-Supervised Comparison
The full potential of the DA+RF is reflected in semi-supervised parameter sweep
comparison for simulation model 1 (Figure 2.3 A). Each set of parameters was evaluated
with 10 replicates and 10-fold cross validation for each replicate. With sufficient
unlabeled examples, the DA method’s performance is high, even with very few labeled
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examples. Because of the extreme feature reduction, the traditional classifier on top of the
DA is able to reach its learning capacity with very few labeled patients (Figure 2.3 A).

Figure 2.3: Classification AUC in relation to the number of labeled patients under simulation
model 1.
(RF – Random Forest, NN – Nearest Neighbors, DA – 2-node DA + Random Forest, SVM –
Support Vector Machine). Unsupervised pre-training of the 2-node DA was performed with
10,000 patients. Notch indicates 95% confidence interval for the median. Whiskers extend 1.5
times past the low and high quartiles. Points outside this range are denoted as dots and represent
outliers. Gray dashed line indicates random choice expected performance (0.5).

Efficient learning from labeled examples is critical in practical use cases because
there are often few well-annotated cases due to the expense of clinician manual review.
The 2-node DA plus random forest also showed strong performance in relation to an
SVM when there were many observed clinical variables (Supp. Fig 3) and when there
were many hidden effects. The SVM again showed the highest performance at very high
numbers (1000 or more) of labeled patients. The advantages of semi-supervised learning
diminish as the number of labeled patients gets closer to the number of total patients. In
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addition, at high patient counts, a DA with more than 2 hidden nodes is required to
capture the structure of the data with higher resolution.

Figure 2.4: Classification accuracy comparisons for models 2-4.
Notch indicates 95% confidence interval for the median. Whiskers extend 1.5 times past the low
and high quartiles. Gray dashed line indicates random choice expected performance (50%). A)
Classification Accuracy of model 2 (1, 2, 4 and 8 effects). B) Classification AUC normalized to
simulation model 2 expected max predictive accuracy (1, 2, 4 and 8 effects). C) Classification
AUC of model 4 (1, 2, 4 and 8 effects). D.) Classification AUC of model 4 (parameter sweep
results for 1, 2, 4 and 8 effects using only the parameter sets with 2,000 labeled patients).
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These patterns repeat across the other simulation models, with more complex models
requiring more hidden nodes to adequately model the structure of the data. In simulation
model 2 (Figure 2.4 A), both 4 and 8 node DAs outperform the 2-node DA. Under Model
3, the 4-node DA is the strongest performing, with median performance 5% better than
the next best traditional classifier. The 4-node DA’s median 95% confidence interval was
above any of the compared methods. Model 4 (Figure 2.4 C-D) was the most difficult to
classify as the classifier had to capture all of the hidden effects to be accurate. In several
cases, no classifier did better than the expected performance of a random classifier. In
fact, the SVM’s average AUC over the entire sweep was statistically indistinguishable
from random performance. As expected, the 2-node performs worse than the 4 and 8node DAs on model 4. The 2-node DA lacks sufficient dimensionality to capture more
than 4 hidden input effects.
Clinical records often have empty fields, so algorithms must be robust to missing
data. We evaluated the DA’s robustness in this situation. The DA is robust to missing
data maintaining near-max classification performance across the missingness proportions
tested (Supp. Fig 4). For these simulation models, the mean imputation used for non-DA
approaches is an ideal strategy. DAs and SVMs show consistent performance even as the
percent of data missing increases, suggesting that the DA is at least as robust as the ideal
imputation method.

2.4.4.   Simulated Subtype Clustering Visualization
We evaluated the DAPS’ ability to cluster patients for subtype identification. To
perform this analysis, we simulated 5,000 cases from each of two different models (1 and
2) to represent a disease with two subtypes. An additional 5,000 controls were simulated.
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We then visualized the DA constructed from this set of patients using PCA followed by tSNE. In the input data, the subtypes are relatively overlapping (Figure 2.5 A). A DA with
two nodes was also unable to separate this number of subtypes (Figure 2.5 B).
Visualizations constructed from DAs with three (Figure 2.5 C) or four (Figure 2.5 D)
nodes were able to effectively separate both subtypes of cases from each other and from
controls.

A.#PCA##
Only#

C.#3#Hidden##
Nodes#

B.#2#
Hidden##
Nodes#

D.#4#Hidden##
Nodes#

Figure 2.5: Case vs. Control clustering of 2 disease states and 1 healthy state.
Clustering via principal components analysis and t-distributed stochastic neighbor embedding
after training the DA for controls and cases generated from a combination of models 1 and 2.
Controls are shown in yellow, subtype 1 (model 1) is shown in red, subtype 2 (model 2) is shown
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in blue. A). Raw input. B.) 1,000 training epochs with 2 hidden nodes. C.) 1,000 training epochs
with 3 hidden nodes. D.) 1,000 training epochs with 4 hidden nodes.

2.4.5.   ALS Survival Analysis
We evaluated the DAPS’ ability to quantitatively predict ALS patient survival
(Figure 6) with ten-fold cross validation. Both models used a random forest regressor to
predict survival to compare predictions between the raw imputed data and the hidden
layer of a 250 node DA.

A.

Figure 2.6: Prediction comparison of ALS survival between DA constructed and raw features.
A.) Ten-fold cross validation survival prediction quantification. Mean absolute error in days.
Notch indicates 95% confidence interval for the median. Whiskers extend 1.5 times past the low
and high quartiles. Points outside this range are denoted as dots and represent outliers.

In order to visualize the basis for improved prediction, we performed t-SNE
clustering to compare PCA with the hidden layer of the DA (Figure 7 A-B, Supp. Fig. 7).
The visualization constructed from the hidden layer of the DA shows space defined by
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the DA separated several clear clusters with low patient survival as well as a more
heterogeneous cluster with longer survival. PCA applied to the raw input produced some
patterns but did not produce any clear clustering by survival.

A.

B.

Figure 2.7: ALS Survival Visualization (Raw vs. Constructed Features).
A.) PCA (2 components) followed by t-SNE. B.) t-SNE of the DA (250 nodes) hidden layer. All
cluster coloring was determined by rank of days survived. Light colors indicate longer survival.

  Summary and Future Directions.
We presented a semi-supervised learning approach using DAs to model patients in
the EHR. The benefits of the method presented in this work are; 1) It is relatively
inexpensive to perform analysis on large amounts of unlabeled EHR data; 2) It is
expensive to have data labeled at a research quality by a clinician; 3) The DA+RF has
strong performance when there are many unlabeled samples and few labeled samples.
Competitive supervised classification accuracy with a large degree of feature
reduction indicates the DA successfully learned the structure of the high-dimensional
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EHR data. DAs are particularly well suited to the EHR because their unsupervised nature
allows the formation of a semi-supervised classifier and the ability to utilize large unannotated patient populations to improve classification accuracy. The dimensionality
reduction of DAs allows clustering of the reduced feature set for the visualization and
determination of subtypes. These clusters may reveal disease subtypes, fine-tuned targets
for genotype-phenotype association. The DA models are easily de-constructible because
they use a simple model for the traditional classifier with transparent node compositions
that can be traced back to inputs. In addition, our method proposes a straightforward
modification to the DA to enable it to process missing data without imputation.
PheWASs are a powerful tool to leverage the vast clinical data contained in the
electronic health record but currently suffer from the reliance on billing codes or manual
clinician annotation. Denny et al. (25) call out the need for increased accuracy in
phenotype definition in the original PheWAS publication, particularly for rare
phenotypes or phenotypes that do not directly correspond with a billing code. In addition,
several studies have found increased genetic linkage via subtyping (9, 12, 13, 36–38). Li
et al. (6) presented a powerful example of EHR subtyping of patients with type 2 diabetes
using a similar methodology, but they utilized Ayasdi, a commercial, closed source
topology data analysis software tool. Our method is built on free, open source libraries
that will continue to be improved and our software is accessible for the research
community.
DA nodes and clusters of nodes provide composite variables that may better
approximate and represent the condition of the subject. These additional phenotype
targets may provide more homogeneous targets for genotype associations. Beyond
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genotype to phenotype association, these visualizations may also help clinicians to
understand the level of heterogeneity for a specific disease and to make treatment
associations among sub-clusters of patients. While further work is required to analyze the
makeup and meaning of the ALS survival clusters recognized by DAPS, they suggest a
helpful starting point for investigation.
Our work provides an important contribution but additional analysis and challenges
remain. The transition from simulated data and relatively homogenous clinical trial data
to diverse multi-disease real world clinical data will likely require additional steps. In
addition, in our simulations we assume a preprocessing step has already been performed
to handle the compound structure present in the EHR. This step is necessary to transform
categorical, free text, images and temporal data to suitable input for the DA. The PROACT ALS clinical trial data does not currently include any free text or images. Raw EHR
data will not be as complete or clean as either clinical trial or simulated data. Despite
these challenges, autoencoders have been shown to effectively denoise data (60, 61), and
may also be well suited to noisy EHR-derived data.
Future work will focus on developing tools to examine and interpret constructed
phenotypes (hidden nodes) and clusters. In addition, we will develop a framework for
evaluating the significance of constructed clusters for genotype to phenotype association.
We anticipate high weights indicate important contributors to node construction revealing
relevant combinations of input features. Finally, we will construct a scheme for
determining optimal hyper parameter (i.e. hidden node count) selection.
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  Motivation and Introduction
Missing data present a challenge to researchers in many fields and this challenge is
growing as datasets increase in size and scope. This is especially problematic for
electronic health records (EHRs), where missing values frequently outnumber observed
values, and the absence of an observation can be caused by a variety of mechanisms that
may or may not be informative. EHRs were designed to record and improve patient care
and streamline billing, and not as resources for research(28) thus there are significant
challenges using these data to gain a better understanding of human health. As EHR data
become an increasingly utilized as a source of phenotypic information for biomedical
research(62) it is crucial to develop strategies for coping with missing data.
Clinical laboratory assays are a particularly rich data source within the EHR, but
they also tend to have large amounts missing data. These data may be missing for many
different reasons. Some tests are used for routine screening but screening may be biased.
Other tests are only conducted if they are clinically relevant to very specific ailments.
Patients may also receive care at multiple healthcare systems, resulting in information
gaps at each institution. Age, sex, socioeconomic status, access to care, and medical
conditions can all impact how comprehensive the data is for a given patient.
Aside from the uncertainty associated with a variable that is not observed, many
analytical methods, such as regression or principal components analysis are designed to
operate on a complete dataset. The easiest way to implement these procedures is to
remove variables with missing values or remove individuals with missing values.
Eliminating variables is justifiable in many situations, especially if a given variable has a
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large proportion of missing values, but doing so may restrict the scope and power of a
study. Removing individuals with missing data is another option known as complete case
analysis. This is generally not recommended unless the fraction of individuals that will
be removed is small enough to be considered trivial, or there is good reason to believe
that the absence of a value is due to random chance. If there are any differences between
individuals with and without observations, complete case analysis will be biased. For
example, if only patients with severe symptoms receive a certain test, removing patients
with missing values is equivalent to removing the healthy patients.
An alternative is to fill the missing fields with estimates. This process, called
imputation, requires a model that generally makes assumptions about why only some
values are observed. These missingness mechanisms fall somewhere in a spectrum
between three scenarios (Figure 3.1). When data is missing in a manner completely
unrelated to both the observed and unobserved values, it is considered to be missing
completely at random (MCAR) (63, 64). When data are MCAR, the observed data
represent a random, unbiased sample of the population, but this is rarely encountered in
practice. Conversely, data missing not at random (MNAR) refers to a situation where the
probability of observing a data point depends on the value of that data point (65). In this
case, the mechanism responsible for the missing data is biased and should not be
considered ignorable (66). For example, rheumatoid factor is an antibody detectable in
blood, and the concentration of this antibody is correlated with the presence and severity
of rheumatoid arthritis. This test is typically performed only on patients with some
indication of rheumatoid arthritis. Thus, patients with high rheumatoid factor levels are
more likely to have rheumatoid factor measures.
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A more complicated scenario can arise when multiple variables are available. If the
probability of observing a data point does not depend on the value of that data point, after
conditioning on one or more additional variables, then that data is said to be missing at
random (MAR) (65).

For example, a variable, X, may be MNAR if considered in

isolation. However, if we observe another variable, Y, that explains some of the variation
in X such that after controlling for the effect of Y, the probability of observing X is no
longer related to its value, X is said to be MAR. In this way, Y can transform X from
MNAR to MAR. There is no way to prove that X is randomly sampled after
conditioning on covariates unless we measure some of the unobserved values, but strong
correlations, ability to explain missingness, and domain knowledge may provide evidence
of that the data are MAR.
Imputation methods assume specific mechanisms of missingness and assumption
violations can lead to bias in the results of downstream analyses that can be difficult to
predict (67, 68). Variances of imputed values are often underestimated causing
artificially low p-values (69). Additionally, for data MNAR, the observed values have a
different distribution than the missing values. To cope with this, a model can be
specified to represent the missing data mechanism, but these models can be difficult to
evaluate and may have a large impact on results. Great caution should be taken when
handling missing data, particularly data that are MNAR. Most imputation methods
assume that data are MAR or MCAR, but it is worth reiterating that these are all idealized
states and real data invariably fall somewhere in between (Figure 3.1).
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Figure 3.1: Mechanisms of missing data.
Two general paradigms are commonly used to describe missing data. Missing data are considered
ignorable if the probability of observing a variable has no relation to the value of the observed
variable, and are considered non-ignorable otherwise. The second paradigm divides missingness
into three categories: missing completely at random (MCAR: the probability of observing a
variable is not dependent on its value or other observed values), missing at random (MAR: the
probability of observing a variable is not dependent on its own value after conditioning on other
observed variables), and missing not at random (MNAR: the probability of observing a variable
is dependent on its value, even after conditioning on other observed variables). The X-axis
indicates the extent to which a given value being observed depends upon other the values of other
observed variables. The Y-axis indicates the extent to which a given value being observed
depends upon its own value.

  Characterizing and Managing Missing Structured Data in Electronic
Health Records.
3.2.1.   Abstract
Missing data is a challenge for all studies; however, this is especially true for
electronic health record (EHR) based analyses. Failure to appropriately consider missing
data can lead to biased results. Here, we provide detailed procedures for when and how to
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conduct imputation of EHR data. We demonstrate how the mechanism of missingness
can be assessed, evaluate the performance of a variety of imputation methods, and
describe some of the most frequent problems that can be encountered. We analyzed
clinical lab measures from 602,366 patients in the Geisinger Health System EHR. Using
these data, we constructed a representative set of complete cases and assessed the
performance of 12 different imputation methods for missing data that was simulated
based on 4 mechanisms of missingness. Our results show that several methods including
variations of Multivariate Imputation by Chained Equations (MICE) and softImpute
consistently imputed missing values with low error; however, only a subset of the MICE
methods were suitable for multiple imputation. The analyses described provide an outline
of considerations for dealing with missing EHR data, steps that researchers can perform
to characterize missingness within their own data, and an evaluation of methods that can
be applied to impute clinical data. While the performance of methods may vary between
datasets, the process we describe can be generalized to the majority of structured data
types that exist in EHRs and all of our methods and code are publicly available.
3.2.2.   Materials and Methods
3.2.2.1.  

Source Code

Source code to reproduce the analyses in this work are provided in our repository
(https://github.com/EpistasisLab/imputation) under a permissive open source license. In
addition, Continuous Analysis(70) was used to generate Docker images matching the
environment of the original analysis, and to create intermediate results and logs. These
artifacts are freely available (https://hub.docker.com/r/brettbj/ehr-imputation/ and archive
version 10.6084/m9.figshare.5165653).
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3.2.2.2.  

EHR data processing

All clinical laboratory assays were mapped to LOINC (Logical Observation
Identifiers Names and Codes). We restricted our analysis only to outpatient lab results to
minimize the effects of extreme results from inpatient and emergency department data.
We used all laboratory results between August 8th, 1996 and March 3rd, 2016. We
excluded any codes for which less than 0.5% of patients had a result. The resulting
dataset consisted of 669,212 individuals and 143 laboratory assays. 	
  	
  	
  	
  
We next removed any lab results that occurred prior to patient’s 18th birthday or
after their 90th. In cases where a date of death was present, we also removed any lab
results that occurred within one year of death as we found that the frequency of
observations often spiked during this period and the values for certain labs were altered
for patients near death. For each patient’s clinical lab measures, a median date of
observation was then calculated based on all of their remaining lab results. We defined a
temporal window of observation by removing any lab results that were recorded more
than 5 years from the median date. We then calculated the median result of the remaining
labs for each patient. Finally, we calculated the mean BMI of each patient, and dropped
any patients whose sex was unknown. As each variable had a different scale and many
deviated from normality, we applied Box-Cox and Z-transformations to all variables.
The final dataset used for all downstream analyses contained 602,366 patients and 146
variables (age, sex, BMI, and 143 laboratory measures).
3.2.2.3.  

Variable selection

We first ranked the labs by total missingness. At each rank we calculated the percent
of complete cases for the set including all lower ranked labs. We also built a random
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forest classifier to predict the missingness of each variable. Based on these results, in
conjunction with domain knowledge, we selected 28 variables that provided a reasonable
trade-off between quantity and completeness and were deemed to be largely MAR.
3.2.2.4.  

Predicting the presence of data

For each clinical lab, we used the default scikit-learn (71) random forest classifier, to
predict whether a specific value would be present or absent. Each lab measure was
converted to a binary label vector based on whether the measure was recorded or not.
The values of all other labs, excluding co-members of a panel, were used as the training
matrix input to the random forest. This process was repeated for each lab test using 10fold cross validation. Prediction accuracy was assessed by the area under the receiver
operator characteristic (AUC ROC), and the results for each variable relate to the degree
of MNAR, MAR, or MCAR present.
3.2.2.5.  

Sampling of complete cases

To generate a set of complete cases that resembled the whole population, we
randomly sampled 100,000 patients without replacement. We then matched each of these
individuals to the most similar patient who had a value for each of the 28 most common
labs by matching sex and finding the minimal Euclidean distance of age and BMI.
3.2.2.6.  

Simulation of missing data

Within the sampled complete cases, we selected the data for removal by four
mechanisms:
Simulation 1: Missing Completely at Random (MCAR)
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We replaced values with NAN at random. This procedure was repeated 10 times
each for 10%, 20%, 30%, 40%, and 50% missingness yielding 50 simulated
datasets.
Simulation 2: Missing at Random (MAR)
We selected two columns (A and B). When column A had a value in the highest
quartile of values for this lab, we replaced 50% of the values selected at random
from column B with NAN. The procedure was repeated for each quartile and
each lab combination yielding 3024 simulated datasets.
Simulation 3: Missing not at Random (MNAR)
We selected a column and a quartile. When the column’s value was in the
quartile we replaced it with NAN 50% of the time. This procedure was repeated
for each of the 4 quartiles of each of the 28 labs generating a total 112 total
simulations of missingness.
Simulation 4: Missingness based on real data observations
From our sampled complete cases dataset, we took each patient and matched them
to the nearest neighbor, excluding self matches, in the entire set of observed data
based on their sex, age, and BMI. We then replaced any lab value with NAN if it
was absent for the matched patient in the original data.
3.2.2.7.  

Imputation of Missing Data

Using our simulated datasets (Simulations 1 - 4) we compared 18 common
imputation methods (representative 12 methods are shown in primary figures) from the
fancyimpute (72) and the Multivariate Imputation by Chained Equations (MICE) (73)
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packages. A full list of imputation methods and the parameters used for each are in
Supplementary Table 1.
3.2.3.   Results
Our first step was to select a subset of the 143 lab measures for which imputation
would be a reasonable approach. We began by ranking the clinical lab measures in
descending order by the number of patients who had an observed value for that lab. At
each rank, we plotted the percent of individuals missing a value for that lab as well as the
percent of complete cases when that given lab was joined with all of the labs of lower
rank. These plots showed that the best tradeoff between quantity of data and
completeness would fall between 20 and 30 variables (Figure 3.2 A).
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Figure 3.2: Summary of missing data for 143 clinical lab measures in the Geisinger Health
System EHR.
A.) After ranking the clinical laboratory measures by the number of total results, the percent of
patients missing a result for each lab was plotted (red points). At each rank, the percent of
complete cases for all labs of equal or lower rank were also plotted (blue points). Only variables
with a rank of 75 or less are shown. The vertical bar indicates the 28 labs that were selected for
further analysis. B.) The full distribution of patient median ages is shown in blue and the fraction
of individuals in each age group that had a complete set of observations for labs 1-28 are shown
in red. C.) Within the 28 labs that were selected for imputation analyses, the mean number of
missing labs is depicted as a function of age. D.) Within the 28 labs that were selected for
imputation, the mean number of missing labs is depicted as a function of BMI. E.) Accuracy of
a random forest predicting the presence or absence of all 143 laboratory tests. F.) Accuracy of a
random forest predicting the presence or absence of the top 28 laboratory tests.
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Table 3.1: LOINC codes and descriptions of the most frequently ordered clinical laboratory
measurements. The assays are ranked from the most common to the least.

As age, sex, and BMI have a considerable impact on what clinical lab measures are
collected, we evaluated the relationship between missingness and these covariates (Figure
3.2 B-D). We also used a random forest approach to predicted the presence or absence of
each measure based on the values of the other observed measures. MCAR data is not
predictable, resulting in ROC AUC near 0.5. Only 38 of the 143 labs had ROC AUCs
less than 0.55 (Figure 3.2 E). Very high ROC AUC are most consistent with data that are
MAR. For the top 30 candidate labs based on the number of complete cases, the mean
ROC AUC was 0.82. This suggested that the observed data could explain much of the
mechanism responsible for the missing data within this set. We ultimately decided not to
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include the 29th ranked lab, specific gravity of urine (2965-2), since it had a ROC AUC of
only 0.69 and is typically used for screening only within urology or nephrology
departments (R. Levy MD, personal communication). We did include the lipid measures
(the 25th-28th ranked labs) since they had ROC AUC values near 0.82 and they are
recommended for screening of all patients depending on age, sex, and BMI(74). Our data
confirm that age, sex, and BMI are all predictive of the presence of lipid measures
(Supplementary Figure 1 A-B).

	
  

To assess the accuracy of imputation methods, we required known values to compare
with imputed values. Thus, we generated a set of complete cases from the 28 variables
we selected based on our characterization of data missingness. Since the set of complete
cases differed from the broader population (Figure 3.2 B-D), we used sampling and Knearest neighbors matching to generate a sample of the complete cases that resembled the
entire population. We then simulated missing data within this set based on 4
mechanisms: MCAR, MAR, MNAR, and realistic patterns based on the original data.
We evaluated our ability to predict the presence of each value in the simulated
datasets so that we could compare patterns with the real data. These simulations
confirmed that our MCAR simulation had low ROC AUC (Figure 3.3 A). The MAR data
(Figure 3.3 B) and MNAR data (Figure 3.3 C) were often well predicted, particularly for
the MAR data, and when data were missing from the tails of distributions. The AUCs
rarely exceeded 0.75 in the MNAR simulations while values above 0.75 were common in
the MAR simulations. This provided additional support to our decision to include the top
28 lab measures, since they all have AUCs between 0.9 and 0.75, which was outside the
range of nearly all MNAR simulations (Figure 3.2 F and Figure 3.3 C).
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Figure 3.3: Ability to predict variable presence for each of the three types of missing data.
A.)   MCAR simulation B.) MAR simulation C.) MNAR simulation.

We chose to test the accuracy of several methods from two popular and freely
available libraries: the Multivariate Imputation by Chained Equations (MICE) package
for R and the fancyimpute library for python. We first applied each of these methods
across simulations 1-3. For each combination, the overall root mean squared errors are
depicted in Figure 3.4. A breakdown of all the methods and parameters are shown in
Supplementary Table 1 with results in Supplementary Figures 3-21.
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Figure 3.4: Imputation accuracy measured by RMSE across simulations 1-3.
Imputation accuracy measured by RMSE across simulations 1-3. A.) Missing Completely at
Random (MCAR) B.) Missing at Random (MAR) C.) Missing Not at Random (MNAR)

We next measured imputation accuracy based on the patterns of missingness that
were observed in the real data (Figure 3.5). The main difference compared to simulations
1-3 was lower error for some of the deterministic methods (Mean, Median, and KNN). It
is worth mentioning that the error was highly dependent upon the variable that was being
imputed. Specifically for the fancyimpute MICE PMM method, multicollinearity within
some of the variables caused convergence failures that led to extremely large errors
(Figure 3.5, method 8). These factors were relatively easy to address in the R package
MICE-PMM method by adjusting the predictor matrix (73).
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Figure 3.5: Imputation error (RMSE) for a subset of 10,000 patients from simulation 4.
Twelve imputation methods were tested (X-axis) and colors indicate how the error varied
between different lab measures (LOINC codes). The black line shows the theoretical error from
random sampling.

In addition to evaluating the accuracy of imputation, it is also important to estimate
the uncertainty associated imputation. One approach to address this is multiple
imputation, where each data point is imputed multiple times using a nondeterministic
method. This allows for the calculation of a confidence interval for any downstream
result of interest. To determine if each method properly captured the true uncertainty of
the data, we compared the error between an imputed dataset and the observed data with
the error between two sets of imputed values for each method (Figure 3.6). If these errors
are equal, then multiple imputation is likely producing good estimates of uncertainty. If,
however, the error between two imputed datasets is less than that between each imputed
dataset and the known values, then the imputation method is likely underestimating the
variance.
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Figure 3.6: Assessment of multiple imputation for each method.
Using simulation 4, we imputed missing values multiple times with each method. The RMSEs
between each imputed dataset and the observed values are shown on the X-axis and the RMSEs
between two sets of imputed data are shown on the Y-axis. The axis scales vary between panels
to better show the range of variation. Each lab test (LOINC) is indicated by the color of the
points. The diagonal line represents unity. Panels are ordered by each method’s mean deviation
(MD) with unity, indicated in the top left corner of each panel.

Our results (Figure 3.6) demonstrate that many of the imputation methods are not
suitable for multiple imputation. Three of the methods that had the lowest error in the
idealized MCAR, MAR, and MNAR simulations (soft impute, MICE col (FI), MICE
norm.pred (R)) were found to have minimal variation between imputations. This was
also true of KNN, SVD, mean, and median imputation. Only three methods (random
sampling, MICE norm (R), and MICE pmm (R)) seemed to have similar error between
the multiple imputations and the observed data and thus appear to be unbiased. The latter
two had very similar performance and are the best candidates for multiple imputation.
Two methods had intermediate performance. The MICE RF (R) was similar to several
other MICE methods in terms of error relative to the observed data but it produced
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slightly less variation between each imputed dataset. This seemed to affect some
variables more than other but there was no obvious pattern. The MICE pmm (FI) was not
deterministic but it did seem to achieve low error at the expense of increased bias. In this
case, the variables that could be imputed with the lowest error also seemed to have the
most bias. Since this method claims to be a reimplementation of the MICE pmm (R)
method, this may be due to multicolinearity among the variables that could not easily be
accounted for as there was no simple way to alter the predictor matrix.
3.2.1.   Discussion
It is not possible, or even desirable, to choose “the best” imputation method. There
are many considerations that may not be generalizable between different sets of data;
however, we can draw some general conclusions about how different methods compare
in terms of error, bias, complexity, and difficulty of implementation. Based on our
results, there seem to be three broad categories of methods.
The first category are the simple, deterministic, methods. These include mean or
median imputation and K-nearest neighbors. The idea behind these methods is that the
central tendency of a distribution will be good guess for any unobserved data point.
Imputing mean or median values is very easy to implement this but may lead to severe
bias and large errors if the unobserved data are more likely to come from the tails of the
observed distribution (Figure 3.5 A-C, methods 2-5). It will also cause the variance of
the distribution to be underestimated if more than a small fraction of the data are missing.
Since these methods are deterministic, they are also not suitable for multiple imputation
since no estimate of the uncertainty in the results of any downstream analyses can be
made (Figure 3.6, bottom row).
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KNN is similar to mean imputation but based on the idea that there may be groups of
individuals that are similar to each other. The value of a missing data point can be
estimated by identifying other individuals who have that measure and appear similar to
the unmeasured individual based on values of variables observed in both. A group of
similar individuals are thus identified and their values are averaged to provide an estimate
of the missing value. This generally provides lower error than taking the mean of all
individuals, but the choice of K can be difficult to specify. Our simulations suggest that
the optimal value can range from less than 1% of the population to more than 50% the
population depending on the mechanism of missingness.
KNN is a popular choice for imputation and has been shown to perform very well in
some types of data (75, 76) but it was not particularly well suited for our data, regardless
of the choice of K. This may due to issues of data dimensionality (77) or it may be that
human beings do not fall into well separated groups based on their clinical lab results.
This method is also not currently suitable for large datasets. The first step is to build a
distance matrix for all pairs of individuals that is stored in RAM, and the size of the
distance matrix scales with n2.
There are also many different methods for calculating distance and the optimal
choice may vary widely from one type of data to another. The method that we
implemented uses the mean squared linear distance across all pairs of shared
observations. While this is probably the best choice when the number of shared features
varies between individuals, it assumes that all variables are equal in their ability to
capture similarities between individuals regardless of what variable is being imputed.
This is certainly not a realistic assumption for our dataset which further points to the fact
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that imputation is not plug and play and analysis must be done before handling missing
data.
The second broad category of algorithms could be called the sophisticated,
deterministic methods. These include SVD, soft impute, and MICE col/norm.predict.
They tend to rely on either multivariate regression and/or projection of the data into a
space of lower dimension. SVD performed poorly compared to its counterparts and
sometimes produced errors greater than simple random sampling (Figure 3.5, method 5).
The reasons for this are not clear, but we cannot currently recommend this method. Soft
impute and MICE col/norm.predict were among the lowest error methods in all of our
simulations (Figure 3.5, methods 6-7). The main limitation of these methods are that
they cannot be used for multiple imputation (Figure 3.6, middle row).
The third broad category of algorithms were the stochastic methods which included
random sampling and most of the remaining methods in the MICE library. The random
sampling method almost always produced the highest error (Figure 3.4-3.5, method 1)
but it has the advantage of being easy to implement and it requires no parameter
selection. The MICE methods based on predictive mean matching, random forests, and
bayesian linear regression tended to perform similarly in terms of error in most of our
simulations (Figure 3.4-3.5, methods 10-12).
Imputation methods that involve some type of stochastic sampling allow for a
fundamentally different type of analysis called multiple imputation. In this paradigm,
multiple imputed datasets (a minimum of 3 and often 10-20 depending of the percentage
of missing data)(78–80) are generated and each is analyzed in the same way. At the end
of all downstream analyses, the results are then compared. Typically, the ultimate result
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of interest is supported by a p-value, a regression coefficient, an odds ratio, etc. In the
case of a multiply imputed dataset, the researcher will have several test statistics that can
be used to estimate a confidence interval for the result.
Multiple imputation has been gaining traction over the years and the MICE (multiple
imputation by chained equations) package has become one of the most popular choices
for implementing this procedure. This package is very powerful and very well
documented(73) but like all methods for imputation, caution must be exercised. There
also seems to be some confusion surrounding the concept of MICE. It is not a single
algorithm but rather a framework for applying a variety of algorithms. Each missing
value for a variable of interest is imputed by considering the other variables that were
observed for that individual, the observed values of the variable of interest in other
individuals, and/or the relationships between the variables. This procedure is applied for
each missing value in one variable, and then to each subsequent variable. This entire
process is then repeated for a number of iterations such that the values imputed in the first
iteration can update the estimates for the second iteration. The result is a chain of
imputed datasets and this entire process is typically performed in parallel so that multiple
chains are generated.
In MICE, there are a number of choices that must be made and care should taken to
evaluate the results. The first obvious choice is the method (i.e. equation). Many
methods are available in the base package, additional methods can be added from other
packages [https://cran.r-project.org/web/packages/miceadds/index.html], and users can
even define their own. These methods could be extended in theory to include any of the
previously described algorithms and the base package already includes random sampling
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and mean imputation. We thoroughly evaluated three methods in the context of our
dataset: predictive mean matching (pmm), bayesian linear regression (norm), and random
forest (rf).
PMM is the default choice and popular since it can be used on a mixture of numeric
and categorical variables. We found PMM to have a good trade-off between error and
bias, but for our dataset it was critical to remove several variables from the predictor
matrix due to strong correlations and multicolinearity. Bayesian regression performed
similarly but was less sensitive to these issues. If a dataset contains only numeric values,
bayesian regression may be a safer option. Random forest tended to produce results that
were slightly biased for a subset of the variables without an appreciable reduction in
error. Aside from random sampling, none of the other methods we evaluated were
suitable for multiple imputation (Figure 3.6).
While the minimization of error in the imputed data is the primary goal, a singular
focus on this objective is likely to lead to bias. For each missing value, it is also
important to estimate the uncertainty associated with it. This can be achieved by multiple
imputation using an algorithm that incorporates stochastic processes. Multiple
imputation has become the field standard because it provide confidence intervals for the
results of downstream analyses. One should not naively assume that any stochastic
process is free of bias. It is important to check that multiple imputation is providing
variability that corresponds to the actual uncertainty of the imputed values using a set of
simulated data.
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  Missing Data imputation in the Electronic Health Record Using
Deeply Learned Autoencoders.
3.3.1.   Abstract
Electronic health records (EHRs) have become a vital source of patient outcome data
but the widespread prevalence of missing data presents a major challenge. Different
causes of missing data in the EHR data may introduce unintentional bias. Here, we
compare the effectiveness of popular multiple imputation strategies with a deeply learned
autoencoder using the Pooled Resource Open-Access ALS Clinical Trials Database
(PRO-ACT). PRO-ACT is particularly interesting because it includes data across 23
different clinical trials. To evaluate performance, we examined imputation accuracy for
known values simulated to be either missing completely at random or missing not at
random. We also compared ALS disease progression prediction across different
imputation models. Autoencoders showed strong performance for imputation accuracy
and contributed to the strongest disease progression predictor. Finally, we show that
despite clinical heterogeneity, ALS disease progression appears homogenous with time
from onset being the most important predictor.

3.3.2.   ALS and the Pooled Resource Open-access Clinical Trials
We evaluate each of the imputation methods on the ALS Pooled Resource Openaccess Clinical Trials (PRO-ACT). Pooled clinical trial datasets present an ideal option
for evaluating EHR imputation strategies because they include patients from differing
environments with potential systematic biases. In addition, clinical trials represent the
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gold standard for data collection making it possible to spike-in missing data while
maintaining enough signal to evaluate imputation techniques.
Prize4Life and the Neurological Clinical Research Institute (NCRI) at Massachusetts
General Hospital created the Pooled Resource Open-Access ALS Clincial Trials (PROACT) platform with funding from the ALS Therapy Alliance in and in partnership with
the Northeast ALS Consortium. The PRO-ACT project was designed to empower
translational ALS research and includes data from 23 clinical trials and 10,723 patients.
In this work, we use the subset of 1,824 patients included in the Prize4Life
challenges(81).
ALS is a progressive neurodegenerative disorder affecting both the upper and lower
motor neurons causing muscle weakness, paralysis and leading to death(81). ALS
patients typically survive only 3 to 5 years from disease onset and show large degrees of
clinical heterogeneity(82–85).
A common measure used to monitor an ALS patient’s condition is the ALS
functional rating scale (ALSFRS)(86, 87). The ALSFRS consists of 10 tests scored from
0-4 assessing patients’ self-sufficiency in categories including: feeding, grooming,
ambulation and communication. The change over time, or slope, is commonly used as a
statistic to represent ALS progression.

3.3.3.   Methods
We compare and evaluate a variety of methods to impute missing data in the EHR.
We spiked-in missing data to the PRO-ACT dataset, and evaluated each approach’s
performance imputing known data. We also evaluated prediction accuracy using each of
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the imputation methods on the ALSFRS. Each of these is described in detail below and
all analysis was run using freely available open source library packages, DAPS(88),
FancyImpute(72), Keras(89) and Scikit-learn(56).
3.3.3.1.  

Data preparation and standardization

The PRO-ACT dataset includes patient demographic data, family history,
concomitant medications, vital sign measurements, laboratory results, and patient history
(disease onset etc.). PRO-ACT performed an initial data cleaning and quality assurance
process. This process included extracting quantitative variables, merging laboratory tests
with different names across trials, removable of indecipherable records and converting
units. After processing the PRO-ACT dataset includes only quantitative values
(continuous, binary, ordinal and categorical).
Our analysis encoded categorical variables using Sci-kit learn’s OneHotEncoder(56).
Temporal or repeated measurements were encoded as the mean, minimum, maximum,
count, standard deviation and slope across all measurements, creating 572 features for
each samples. Additional measurements were standardized across scales (i.e. inches to
cm). Non-numeric values in numeric measurements were coerced to numeric values.
Where coercion failed they were replaced by NaN. Input features were normalized and
scaled to be between 0 and 1, with missing features remaining as NaN.
3.3.4.   Imputation Strategies and Evaluations
Autoencoders are a variation of artificial neural networks that learn a distributed
representation of their input(45). They learn parameters to transform the data to a hidden
layer and then reconstruct the original input. By using a hidden layer smaller than the
number of input features, or “bottle-neck” layer the autoencoder is forced to learn the
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most important patterns in the data(53). To prevent overreliance on specific features two
techniques are commonly used. In a denoising autoencoder, noise is added to corrupt a
portion of the inputs(44, 53). Alternatively, a technique called dropout in which random
units and connections are removed from the network forcing it to learn
generalizations(90). Autoencoders were shown to generate useful higher representations
in both simulated and real EHR data. Because autoencoders learn by reconstructing the
original input from a corrupted version, imputation is a natural extension(88, 91).
3.3.4.1.  

Imputing missing data with Autoencoders

We constructed an autoencoder with a modified binary cross entropy cost between
the reconstructed layer z and the input data x to better handle missing data as in BeaulieuJones and Greene (2016) (Formula 1)(88). The modified function takes into account
missing data, with m representing a “missingness” vector; m has a value of 1 where the
data is present and 0 when the data is missing. By multiplying by m and dividing by the
count of present features (sum of m) the result represents the average cost per present
feature. The weights and biases of the autoencoder are trained only on present features
and imputation does not need to be performed prior to training the autoencoder.

𝑐𝑜𝑠𝑡 = 	
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   𝑚0 + (1 − 𝑥0 ) log 1 − 𝑧0 𝑚0 ]	
  /	
  𝑐𝑜𝑢𝑛𝑡(𝑚)	
  

(Formula 1)

With the exception of the modified cost function autoencoders were trained as
described by Vincent et al. with a 100 training epoch patience(44). If a new minimum
cost was not reached in 100 epochs, training was stopped. The autoencoder with dropout
was implemented using the FancyImpute(72) and Keras(89) libraries with a Theano(54,
55) backend.
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We performed a parameter sweep to determine the hyperparameters for the
autoencoder. In the sweep we included autoencoders of one to three hidden layers and
each combination of 2, 4, 10, 100, 200, 500 and 1000 (over-complete representation)
hidden nodes per layer. Autoencoders with two hidden layers made up of 500 nodes each
are shown for all comparisons (Figure 3.7). Dropout levels of 5, 10, 20, 30, 40 and 50%
were evaluated with 20% being shown for all comparisons.
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Figure 3.7 : Schematic structure of the autoencoder used for evaluations.
Autoencoder includes two hidden layers and 20% dropout between each layer.

Binary cross entropy was used for training because it tends to be a better evaluator of
quality when training neural networks(44, 53, 92, 93). We use a root mean squared error
for comparison to other methods to prevent a bias in favor of autoencoders, as most other
methods are not trained with cross entropy.
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3.3.4.2.  

Comparative imputation strategies

We used the FancyImpute(72) libraries implementations for each of the other
imputation strategies:
1.)   IterativeSVD, matrix completion by low rank singular value decomposition
based on SVDImpute(76).
2.)   K-nearest neighbors imputation (KNNimpute), matrix completion by choosing
the mean values of the K closest samples for features where both samples are
present.
3.)   SoftImpute(94), matrix completion by iterative replacement of missing values
with values from a soft-thresholded singular value decomposition.
4.)   Column mean filling.
5.)   Column median filling
The standard implementations of the remaining algorithms in the FancyImpute
library, MICE, Matrix Factorization and Nuclear Norm Minimization are known to be
slow on large matrices and were impractically slow on this dataset(95–99).
We performed a parameter sweep for SVDimpute analyzing ranks of 5, 10, 20, 40
and 80. Ranks of 40 showed the strongest performance with this dataset and are shown
for all comparisons. The parameter sweep for KNNimpute included 1, 3, 5, 7, 15 and 30
neighbors, k of 7 showed the strongest performance of the parameter sweep and is used
for all comparisons.
3.3.4.3.  

Missing Completely at Random Imputation Evaluation

To evaluate imputation accuracy in a missing completely at random environment we
performed trials replacing 10, 20, 30, 40 and 50% of known features at random with
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NaN. We performed each imputation strategy on the data with spiked-in missingness and
evaluated the root mean squared error between the imputed estimates and the original
data. We performed five trials for each amount of spiked-in data (Figure 3.8).
Performance was evaluated using the root mean squared error between the known value
before spiking in missingness and the imputed value.
3.3.4.4.  

Missing Not at Random Imputation Evaluation

To perform a basic imputation simulation where data was missing not at random,
varying percentages (10, 20, 30, 40, and 50%) of features were chosen at random. Half of
the highest or lowest (randomly selected) quartile of values was replaced by NaN at
random. Each imputation strategy was evaluated on five independent spike-in trails.
Performance was evaluated using the root mean squared error between the imputed
values and original values. This type of imputation could occur when the highest or
lowest values represent the normal range and the clinician is able to determine a patient is
normal through other factors. Alternatively, the extreme values could represent a clear
result where an additional is not needed to determine the result. Performance was
evaluated using the root mean squared error between the known value before spiking in
missingness and the predicted value.
3.3.4.5.  

Progression Prediction Evaluation

To predict disease progression as represented by the ALSFRS score slope, we first
imputed the missing data using column mean averaging, column median averaging,
SVDImpute, SoftImpute, KNNimpute, and an autoencoder with dropout. For prediction
purposes, we excluded all ALSFRS score and Forced Vital Capacity-related features.
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We then used the scikit-learn implementation of a random forest regressor(56) to
predict the ALSFRS score slope. The random forest regressor was chosen because four of
the top six teams in the DREAM-Phil Bowen ALS Prediction Prize4Life challenge used
variants of random forest regressors(81). We also compare a random forest regressor
modified to predict progression from the raw data without imputation(100). Ten-fold
cross validation was performed and the root mean squared error between the predicted
slope and actual slope was calculated. We then extracted the top 10 most important
features used in the trained model for analysis (Figure 3.8).
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Figure 3.8: Imputation Evaluation Outline.
A.) Imputation Evaluation. PRO-ACT patient data of 10,723 subjects has known data masked
with spiked in missing data. Imputation strategies are performed in parallel and the RMSE is
calculated between the masked input data and each strategies imputations. B.) Progression
Prediction. PRO-ACT patients are imputed using each strategy. Ten-fold cross validation of a
random forest regressor is performed on imputed patients.

3.3.5.   Results
Most patients were missing approximately half of the features we extracted from the
EHR (Figure 3.9 A). The pooled aspect of the PRO-ACT data is particularly evident in
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the distribution of missing features as different clinical trials collected different amounts
of data. Features tended to be observed in either less than 25% or in greater than 75% of
patients (Figure 3.9 B). Lab tests, in particular, demonstrated high variability of
missingness among patients, with many present in small numbers of patients. It is
impossible to determine the level of each type of missing data that exists, but it is clear
that at least some of data missing is due to clinical factors (trial group etc.). The most
complete features are demographics and family history information, information likely
collected before entry into any of the clinical trials.
A.#

B.#

Figure 3.9: Histogram distribution and rug plot showing the number of patients each feature is
present in.
A.) The number of features each patient has. Ticks at the bottom indicate one patient with the count of
features, bins indicate the number of patients in a range. B.) The number of patients having a recorded value
for each feature. Ticks at the bottom indicate the number of patients a feature is present in, bins indicate the
number of features in a range.

3.3.6.   Missing completely at random spike-in results
Mean, Median and Singular Value Decomposition imputation perform poorly when
data is missing completely at random. However, they do not appear to degrade as the
spike-in ratio increase (Figure 3.10). This is not surprising for mean and median
imputation because missing data is chosen completely at random and is unlikely to have a
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large effect on statistical averages. The autoencoder had the highest imputation
performance despite increasing as the spike-in ratio increased.

Figure 3.10: Effect of the amount of spiked-in missing data on imputation.
Error bars indicate 5-fold cross validation score ranges.

3.3.7.   Not missing at random spike-in results
The trends seen in the missing completely at random experiment largely repeat when
the data is missing not at random. The autoencoder approach shows strong performance
but is closely followed by the KNN, Softimpute and SVD approaches (Figure 3.11).
KNN works by finding the k-nearest neighbors for shared values and taking the mean for
the missing feature. Autoencoders work by learning the optimal network for
reconstruction. Similar input values will have similar hidden node values. This similarity
could explain the relatively even performance between the two methods. In addition to
recognizing similar samples, autoencoders have been shown to perform well when there
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is dependency or correlation between variables(60); this is the scenario when data is
missing not at random. When spike-in ratios increase to high levels the methods begin to
converge to the performance of mean and median imputation. This is likely because too
much of the signal is lost as missing data to learn the correlation structure.

Figure 3.11: Effect of non-random spiked-in missing data on imputation (measured in RMSE).
Autoencoder w/Dropout (2 layer 500 nodes each), SVD – SVDImpute with rank of 40, KNN KNNimpute with 7 neighbors, Mean – Column Mean Averaging, Median – column median
averaging, SI – SoftImpute.

3.3.8.   ALS disease progression
Imputation strategy has a modest but statistically significant impact on the root mean
squared error of ALS disease progression prediction, but the autoencoder approach is the
strongest performing (Figure 3.12). Despite showing poor performance in the imputation
accuracy exercises Singular Value Decomposition does approximately as well as knearest neighbors and SoftImpute in this experiment. A random forest regressor applied
to the raw data is the worst performing, but is not significantly worse than any of the
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methods other than the Autoencoder. In terms of ALS disease progression, imputation
does not appear to have a large effect on prediction, but can be vital to allow the use of
other algorithms (prediction, clustering etc.) without modification.

Figure 3.12: ALS Functional Rating Scale prediction accuracy.
Prediction accuracy shown for an autoencoder, k-nearest neighbors, mean averaging, median
averaging, the raw input including missing values, soft impute and singular value decomposition.
The box indicates inner quartiles with the line representing the median; the whiskers indicate
outer quartiles excluding outliers.

3.3.9.   ALS progression predictive indicators
Nine out of the top ten most important features in the autoencoder-imputed random
forest regressor were among the top fifteen identified in the DREAM Prediction
challenge (Figure 3.13 A). The amount of time using Riluzole was not among the top
fifteen previously identified. Riluzole is the only FDA approved medication for ALS
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treatment but it is believed to have a limited effect on survival(101–103). The finding that
Riluzole is protective of ALS slope indicates some level of efficacy.
Of the top ten most important features, five are missing in more than 50% of patients
in the data set. This is a possible explanation for the improvement shown by
Autoencoders, SVDimpute and KNNimpute over mean imputation.
By far the most important feature for prediction is the time from onset and several
of the most important features are highly correlated with time from onset. ALSFRS
slopes resemble a normal distribution (Figure 3.13 B). When including the entire PROACT dataset, the Kolmogorov-Smirnov test score is 0.05 for patients with negative
slopes. This indicates the progression of the disease is similar to a truncated normal
distribution. We exclude positive slopes because ALS patients do not typically get better,
and signs of doing so are likely the result of measurement error. Despite presenting in
clinically heterogeneous manners, ALS progression as defined by the ALSFRS appears to
be largely homogenous. Patients fall within a relatively normal distribution and have
increasingly negative slopes the longer they ALS.

A.#

B.#

Figure 3.13: Prediction feature importance.
A.) Importance levels of the top 10 features to the random forest regressor with autoencoder
imputed data. B.) Histogram distribution of patient ALSFRS slope levels.
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3.3.10.  Discussion and Conclusions
In this study, we compared the performance of an autoencoder approach with
popular imputation techniques in ALS EHR data. A multi-layer autoencoder with dropout
showed robust imputation performance across a variety of spiked-in missing data
experiments designed to be both completely at random and not at random. Furthermore,
we found that imputation accuracy may not strictly correlate with predictive performance
but the most accurate imputer provided the most accurate predictor. The importance of
imputation is demonstrated by five of the top ten most important features for prediction
being missing in more than 50% of patients.
Increased deterioration of imputation performance for KNNimpute and SVDimpute
with increased missing data is at odds with previous research of imputation in
microarrays(76). Possible explanations include either reaching a threshold of missing
data where the burden is too high for these methods to accurately impute or that a
confounding systematic bias is introduced from the different clinical trials.
This work is a promising first step in utilizing deep learning techniques for missing
data imputation in the EHR but challenges remain. Autoencoders are computationally
intensive, but less so than imputation techniques like MICE, Matrix Factorization and
Nuclear Norm Minimization. With GPU resources, autoencoders train in similar amounts
of time to both KNN and SVD methods for these clinical trials. As data increases,
autoencoder training time increases linearly in line with the number of samples. Methods
like KNN require computing a distance matrix, which increases in exponential time. In
addition, further examination is necessary to determine whether the strong performance
shown by autoencoders is a result of the structure of this pooled clinical trial dataset. The
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subset of 1,800 patients is relatively small and methods may differ in performance
increases with more patients.
This work offers promising results but has several limitations especially because
it specifically analyzes pre-processed pooled clinical trial data. Clinical trials have more
complete and cleaner data than raw EHR. Follow up work should be performed with
other diseases and in the general patient population. These methods have also only been
evaluated for quantitative values; in raw EHR data there will be an additional extraction
step for raw text and qualitative observations that was not necessary due to PRO-ACT’s
preprocessing.
Additional future work will be concentrated on developing tools to better understand
and interpret the structure of the trained autoencoder networks. We anticipate being able
to recognize patterns in the trained weights to see correlation between input features.
Understanding correlation will empower new clustering and visualization opportunities.
Spike-in evaluations can provide a supervised context to otherwise unsupervised learning
problems; further analysis should be performed on the higher-level learned features in the
hidden layers of the autoencoders. We suspect these features may be useful in patient
outcome classification and regression problems.
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Chapter 4.  

Enabling data sharing and reproducible research with private data.

This chapter includes adaptations from:
Beaulieu-Jones, Brett K., and Casey S. Greene. "Reproducibility of computational
workflows is automated using continuous analysis." Nature Biotechnology 35.4 (2017):
342-346. doi: 10.1038/nbt.3780
B.K.B.-J. and C.S.G. conceived the study and designed the solution. B.K.B.-J.
implemented continuous analysis. B.K.B.-J. and C.S.G. wrote, revised and approved the
manuscript.
Supplemental Materials and Online Methods are available at:
https://doi.org/10.1038/nbt.3780#supplementary-information
And
Beaulieu-Jones, B. K., Wu, Z. S., Williams, C., & Greene, C. S. (2017). Privacypreserving generative deep neural networks support clinical data sharing. In review
(2017). Preprint doi: 10.1101/159756.
B.K.B.-J. and C.S.G. conceived the study. B.K.B.-J. And C.W. performed initial
analyses. B.K.B.-J. and Z.S.W. designed and validated the privacy approach. B.K.B.-J.,
C.S.G. and Z.S.W. wrote the manuscript and all authors revised and approved the final
manuscript.
Supplemental Figures are available at: https://doi.org/10.1101/159756

  Motivation
Advancement in science depends on the ability to trust previous work as correct and
accurate. The ability to reproduce the work in question is one factor in building this trust.
When Nature conducted a survey, the vast majority of researchers answered that there ‘is
a reproducibility crisis’ (104). For many experiments, providing a written description of a
protocol is insufficient. Computational experiments can be exceedingly complicated and
software changes over time. Written protocols often fail to explicitly state the version of
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the software used. Even when the version is provided, it may no longer be available.
These issues of computational reproducibility are greatly exacerbated when working with
sensitive data that cannot be shared. Electronic health records are an example of this
“private data”. The rightful necessity to protect patient privacy prohibits sharing any
identifiable data. This presents several challenges. It is difficult to determine whether a
failure to reproduce a previous work is due to a difference in protocol or data. If the error
is in replicating the protocol, readers have no way of knowing which step they diverged
from the original work. We present technical solutions to both issues, 1.) a method that
allows readers to perform analyses in the exact computing environment as the original
authors and to view logs with intermediate results from the original experiment, and 2.) a
method to generate data that closely resembles unshareable private data while preserving
the privacy of study participants.

  Reproducibility of computational workflows is automated using
continuous analysis.
4.2.1.   Abstract
Replication, validation and extension of experiments are crucial for scientific
progress. Computational experiments are scriptable and should be easy to reproduce.
However, computational analyses are designed and run in a specific computing
environment, which may be difficult or impossible to match using written instructions.
We report the development of continuous analysis, a workflow that enables reproducible
computational analyses. Continuous analysis combines Docker, a container technology
akin to virtual machines, with continuous integration, a software development technique,
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to automatically rerun a computational analysis whenever updates or improvements are
made to source code or data. This enables researchers to reproduce results without
contacting the study authors. Continuous analysis allows reviewers, editors or readers to
verify reproducibility without manually downloading and rerunning code and can provide
an audit trail for analyses of data that cannot be shared.
4.2.2.   Introduction
Leading scientific journals have highlighted a need for improved reproducibility
in order to increase confidence in results and reduce the number of retractions(105–109).
In a recent survey, 90% of researchers acknowledged that there ‘is a reproducibility
crisis’(104). Computational reproducibility is the ability to exactly reproduce results
given the same data, as opposed to replication, which requires a new independent
experiment. Computational protocols used for research should be readily reproducible
because all of the steps are scripted into a machine-readable format. However, results can
often only be reproduced with help from the original authors, and reproducing results
requires a substantial time investment. Garijo et al.(110) estimated that it would take 280
hours for a non-expert to reproduce the computational construction of a drug-target
network for Mycobacterium tuberculosis(111). Written descriptions of computational
approaches can be difficult to understand and may lack sufficient details, including data
preprocessing, model parameter selection and software versions, which are crucial for
reproducibility. Indeed, Ioannidis et al.(112) indicated that the outputs of 56% of
microarray gene expression experiments could not be reproduced and another 33% could
only be reproduced with discrepancies. Additionally, Hothorn and Leisch found that
more than 80% of manuscripts did not report software versions(113).
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It has been proposed that open science could aid reproducibility(107, 114). In
open science the data and source code are shared. Intermediate results and project
planning are sometimes also shared(115). Sharing data and source code are necessary, but
not sufficient, to make research reproducible. Even when code and data are shared, it
remains difficult to reproduce results due to variability in computing environments,
operating systems, and the versions of software used during the original analysis. It is
common to use one or more software libraries during a project. Using these libraries
creates a dependency to a particular version of the library; research code often only works
with old versions of these libraries(116). Developers of newer versions may have
renamed functions, resulting in broken code, or changed the way a function works to
yield a slightly different result without returning an error. For example, Python 2 would
perform integer division by default, so 5/2 would return 2. Python 3 performs floatingpoint division by default, so the same 5/2 command now returns 2.5. In addition, old or
broken dependencies can mean that it is not possible for readers or reviewers to recreate
the computational environment used by the authors of a study. In this case it becomes
impossible to validate or extend results.
We first illustrate, using a practical example, the problem of reproducibility of
computational studies. Then we describe the development and validation of a method
named continuous analysis that can address this problem.
4.2.3.   Results
One example illustrating how data-sharing does not automatically make science
reproducible can be found in routine analyses of differential gene expression.
Differential expression analyses are performed first by quantifying RNA levels in two or
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more conditions and then identifying the transcripts with expression levels that are altered
by the experiment. When a DNA microarray is used to measure transcript expression
levels, positions on the array correspond to oligonucleotides of certain sequences, termed
probes. A certain set of probes is used to estimate the expression level of each gene or
transcript. As our understanding of the genome changes, the optimal mapping of probes
to genes or transcripts can change as well.

  

Figure 4.1: Custom CDF version reporting in recent and popular publications.
A.) The 100 most recent publications and the B.) 100 most cited papers citing Dai et al.(117) that
use Custom CDF. Each circle represents one manuscript; color coding indicates the Custom CDF
version used.

Dai et al.(117) publish and maintain a popular source of probe set description files
that are routinely updated (BrainArray Custom CDF). Analyses that fail to report the
probe set version, or that were performed with probe set definitions that are now missing,
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can never be reproduced. We set out to ascertain the extent of this problem through a
literature search. We analyzed the one hundred most recently published papers citing Dai
et al. that were accessible at our institution (Supplementary Data 1). We identified these
manuscripts using Web of Science on November 14, 2016. We recorded the number of
papers that cited a version of Custom CDF, including which version was cited. These
articles adhered to expectations of citing methods appropriately because they cited the
source of their probe set definitions. Of these 100 papers, 49 (49%) specified which
version was used (Figure 4.1 A). These manuscripts reported the use of versions 6, 10,
12, 14, 15, 16, 17, 18, and 19 of the BrainArray Custom CDF. As of November 14, 2016
versions 6 and 12 were no longer available for download on the BrainArray web site. To
determine the extent to which a lack of version reporting of the probe set affects high
impact papers, we analyzed at the one hundred most cited papers that cite Dai et al.
(Supplementary Data 2). We determined the one hundred most cited papers using Web of
Science on November 14, 2016. Of these 100 papers, 36 (36%) specified which version
of the Custom CDF was used (Figure 4.1 B). These manuscripts used versions 4, 6, 7, 8,
10, 11, 12, 13, 14 and 17. Versions 4, 6, 7, 11 and 12 were not available for download as
of November 14, 2016.
In order to evaluate how different BrainArray Custom CDF versions affect the
outcomes of standard analyses, we downloaded a recently published gene expression
dataset (GEO accession number GSE47664). The reported experiment with this dataset
measured gene expression in normal HeLa cells and HeLa cells with TIA1 and TIAR
knocked down(118). We ran the same source code using the same dataset altering only
the version of the BrainArray Custom CDF library (versions 18, 19 and 20). Each version
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identified a different number of significantly altered genes (Figure 4.2 A). There were 15
genes identified as significant in version 19 that were not identified in version 18, and 10
genes identified as significant in version 18 that were not identified version 19. There
were 18 genes identified as significant in version 20 that were not found in version 18
and 14 genes identified as significant in version 18 that were not identified in version 20.
These results indicate that study outcomes are not reproducible without an accurate
version number.

Figure 4.2: Comparison of traditional vs. container based approaches.
Research computing versus container-based approaches for differential gene expression analysis
of HeLa cells. Numbers of significantly differentially expressed genes identified using different
versions of software packages. (a) and a container-based approach with a defined computing
environment (b). n = 3 biological replicates per group (wild-type or double-knockdown HeLa
cells)
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4.2.3.1.  

Using Docker containers improves reproducibility

To improve reproducibility, researchers can maintain dependencies using the free
open-source software tool Docker(116),(42). Docker can be used to create an “image”
that allows users to download and run a container, which is a minimalist virtual machine
with a predefined computing environment. Docker images can be several gigabytes in
size, but once downloaded can be started in a matter of seconds and have minimal
overhead(116). This technology has been widely adopted and is now supported by many
popular cloud providers including Amazon, Google and Microsoft.
Docker wraps software into a container that includes everything the software
needs to run (operating system, system tools, installed software libraries etc.). This allows
the software to run the exact same way in any environment. Boettiger introduced Docker
containers as a path to reproducible research by eliminating dependency management,
remediating issues caused by imprecise documentation, limiting the effects of code rot
(dependencies to specific software library versions) and eliminating barriers to software
reuse(116). In addition, Docker images can be tagged to coincide with software releases
and paper revisions. This means that even as software is updated, the exact computing
environment of a specific older version can be available through the tag of the container’s
revision history.
In order to assess whether using Docker containers could improve reproducibility
of the same experiment we also carried out an analysis of differential gene expression
using Docker containers on mismatched machines(119). This process allows versions to
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be matched, and produces the same number and set of differentially expressed genes
(Figure 4.2 B).
Docker is a useful starting point for reproducible workflows. While it helps to
match the computing environment, users must manually rebuild the environment, rerun
the analysis pipeline, and update the container after each relevant change. In addition, it
does not produce logs of exactly what was run. It also does not automatically track results
alongside the specific versions of the code and data that generated them. In summary,
Docker can provide manual reproducibility when it is used appropriately.
4.2.3.2.  

Continuous Analysis

Our goal when developing continuous analysis was to produce an automatic and
verifiable end-to-end run for computational analyses with minimal start-up costs. The
status quo process requires researchers to perform an analysis and then diligently describe
each step and communicate exact versions of software library dependencies used, which
can be hundreds or thousands of packages for modern operating systems. To sidestep
requiring readers and reviewers to download and install multiple software packages and
datasets, continuous analysis preserves the exact computing environment used for the
original analysis. A Docker container is built at the time of original analysis and thus
includes the exact versions used by the original authors without the risk of packages later
becoming inaccessible. The continuous aspect refers to an analysis being rerun, the
results saved in version control, and the container being automatically updated after any
relevant changes to the software script or data.
Continuous analysis is an extension of continuous integration(120). Continuous
integration is widely used in software development. In this workflow, whenever
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developers update code in a source control repository, an automated build process is
triggered. This automated build process first runs any existing test scripts in an attempt to
catch bugs introduced into software. If there are no tests or the software passes the tests,
the software is automatically sent to remote servers so that users worldwide can access it.
Our continuous analysis workflows (Figure 4.3) use continuous integration
services to run computational analyses, update figures, and publish changes to online
repositories whenever changes are made to the source code used in an experiment. We
provide continuous analysis workflows for popular continuous integration systems that
can be used with multiple types of computing environments including local computing
and cloud computing.

Figure 4.3: Setting up continuous analysis.
Continuous analysis can be set up in three steps. First, the researcher creates a Docker container
with the required software (1). The researcher then configures a continuous integration service to
use this Docker image (2) then pushes code that includes a script capable of running the analyses
from start to finish (3). The continuous integration provider runs the latest version of code in the
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specified Docker environment without manual intervention. This generates a Docker container
with intermediate results that allows anyone to rerun analysis in the same environment, produces
updated figures and stores logs describing what occurred. Example configurations are available
in Online Methods and at https://github.com/greenelab/continuous_analysis.

In the continuous analysis workflows that we developed, a continuous integration
service is used to monitor the source code repository. Whenever a change is made to a
user-specified branch of the repository, the service re-runs the scientific analysis.
Workflows are defined in files written in YAML that specify the configuration
parameters and commands that should be run. The YAML language is widely used by
continuous integration services to specify a human-readable set of instructions. The
continuous analysis YAML files that we have developed for multiple services to enable
users to employ local computing, cloud-based computing, or commercial service
providers.
Each workflow begins by specifying a base Docker image to replicate the
researcher’s computing environment. The YAML files that we developed provide a place
for researchers to choose a base Docker image. Using Docker allows other researchers to
re-run code in a computing environment that matches what the original authors used,
even if they do not duplicate the original authors’ continuous integration configuration.
Next, the continuous analysis workflow YAML files specify one or more shell
commands required to perform the analysis. Researchers can replace the commands in
our examples with their own analytical code. Executing these steps generates the relevant
figures from the analysis. Our YAML implementation of continuous analysis then
updates the remote source code repository by adding figures and results generated during
the run. Finally, a Docker container with the final computing environment is
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automatically updated. This continuous analysis process allows changes to be
automatically tracked as a project proceeds and pairs each result with the source code,
data, and Docker container used to generate it.

Figure 4.4: Reproducible workflows with continuous analysis.
A.,B.) Phylogenetic tree building with four mRNA samples (MouseTw1, HumanTw1,
MouseTw2 and FlyTw) and an additional gene (HumanTw2). C.,D.) RNA-seq differential
expression experiment principal component (PC) analysis before C.) and after D.) addition of a
sample (mT8).

Using continuous integration in this fashion automatically generates a log of
exactly what code was run that is synchronized to the code, data, and computing
environment (Supplemental Figure 1). Version control systems allow for images to be
easily compared, which provides continuous analysis users with the ability to observe
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results before and after changes (Figure 4.4). Interactive development tools, such as
Jupyter(121, 122), RMarkdown(123, 124) and Sweave(125) can be incorporated to
present the code and analysis in a logical graphical manner. For example, we recently
used Jupyter with continuous analysis in our own publication(88) and corresponding
repository(41). Reviewers can follow what was done in an audit fashion without having
to install and run software while having confidence that analyses are reproducible.
When an author is ready to publish their work, they should archive their
repository, which contains the automatically generated results alongside the analytical
source code and scripted commands for data retrieval. With our continuous analysis
workflows, the authors can use the `docker save` command to export the latest static
container, which should also be archived. There are an increasing number of services that
allow digital artifacts to be archived and distributed, including Figshare or Zenodo.
Journals may also allow authors to upload these files as supplementary elements. If the
archiving service used by the authors provides a digital object identifier, future users can
easily cite the computing environment and source code. For example, our continuous
analysis environment(126) and results(127) are available in this fashion with results and
our source code is provided as Supplementary Source Code 1.
This system imposes minimal cost in terms of time and money on the researcher.
Continuous analysis is set up once per project, and will then run automatically for the life
of the project. We provide example YAML workflows for commonly used services.
Researchers can replace the steps in our example analyses with their own commands to
enable automatic reproducibility for their own projects.
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4.2.3.3.  

Setting up continuous analysis

To set up continuous analysis, a researcher needs to do three things. First they
must create a Dockerfile, which specifies the software required for their analysis .
Second, they need to connect a continuous integration service to their version control
system and add a continuous analysis command script to run their analysis. Finally, they
need to save their changes to the version control system. Many researchers already
perform the first and third tasks in the course of standard procedures for computational
research.
The continuous integration system (Figure 4.3) will automatically rerun the
specified analysis with each change, precisely matching the source code and results. It
can also be set to listen and run only when changes are marked in a specific way, e.g. by
committing to a specific ‘staging’ branch. For the first project, continuous analysis can be
set up in less than a day. For subsequent projects, the continuous analysis protocol can be
amended in less than an hour.
We have set up continuous analysis using the free and open source Drone
software on a PC and connected it to the GitHub version control service (detailed
instructions are available in Online Methods). This method is free to users. Our GitHub
repository and Supplementary Source Code include continuous analysis YAML scripts
for local, cloud-based, and full-service paid configurations(127). However, it is important
to note that while full service providers can be set up in minutes, they may impose
computational resource limits or monthly fees. Private installations require configuration
but can scale to a local cluster or cloud service to match the computational complexity of

97

all types of research. With free, open-source continuous integration software(128),
computing resources are the only associated costs.
We suggest a development workflow where continuous analysis runs only on a
selected branch (Supplemental Figure 2). Our example setup configures a “staging”
branch for this purpose. Researchers can push to this branch whenever they would like to
generate results files and figures. If the updates to this branch succeed, the changes –
along with the results of analyses – are then automatically carried over to the master or
production branch and released.
4.2.3.4.  

Reproducible workflows

Following initial setup, continuous analysis can be adopted into existing
workflows that use source control systems. We used continuous analysis in our work
using neural networks to stratify patients based on their electronic health records(41). In
addition, we provide two example analyses using continuous analysis: a phylogenetic tree
building and RNA-seq differential expression analysis.
The phylogenetic tree-building example (detailed in Online Methods) aligned 4
mRNA sequences (MouseTw1, HumanTw1, MouseTw2 and FlyTw) using MAFFT(129)
and built a phylogenetic tree with these alignments using PHYLIP(130) (Figure 4.4 A).
After adding an additional sample (HumanTw2), continuous analysis rebuilt the tree
(Figure 4.4 B).
The RNA-seq example (detailed in Online Methods) demonstrated differential
expression analysis between three different organoid models of pancreatic cancer in mice
based on Boi et al.(131) (GEO accession number GSE63348) while reusing source code
from Balli(132). This analysis used kallisto(133), limma(134, 135), and sleuth(136) to
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quantify the transcript counts, performed principal components analysis and ran a
differential expression analysis. The analysis was initially performed with 7 samples
(Figure 4.4 C). An 8th sample was added to show how continuous analysis tracked results
(Figure 4.4 D). This example also demonstrated the ability of continuous analysis to scale
to the analysis of large datasets – this GEO accession includes 150GB of data
(approximately 480 million reads).
4.2.4.   Discussion
Continuous analysis provides a verifiable end-to-end run of scientific software in
a fully specified environment, thereby enabling true reproduction of computational
analyses. Because continuous analysis runs automatically, it can be set up at the start of
any project to provide an audit trail that allows reviewers, editors and readers to assess
reproducibility without a large time commitment. If readers or reviewers need to re-run
the code on their own (e.g. to change a parameter and evaluate the impact on results),
they can easily do so with a Docker container containing the final computing
environment and results that has been automatically kept up to date. Version control
systems enable automatic notification of code updates and new runs to those who “star”
or “watch” a repository on services such as Github, Gitlab, and Bitbucket. Wide adoption
of continuous analysis could conceivably be linked with the peer review and publication
process allowing interested parties to be notified of updates.
Continuous analysis can also be applied to closed data that cannot be released e.g.
patient data. Without continuous analysis, reproducing or replicating computational
analyses based on closed data is dependent on the original authors completely describing
each step, which often becomes relegated to supplementary information. Readers and
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reviewers must then diligently follow complex written instructions without any
confirmation they are on the right track. The pairing of automatically updated containers,
source code, and results with the audit log provides readers with confidence that results
would be replicable if the data were available. This allows independent researchers to
attempt to replicate findings in their own non-public datasets without worrying that a
failure to replicate could be caused by source code or environment differences.
Continuous analysis currently has limitations. It may be impractical to use
continuous analysis at every commit for generic preprocessing steps involving very large
data or analyses requiring particularly high computational costs. In particular, steps that
take days to run or incur substantial costs in computational resources (e.g. genotype
imputation) may be too expensive for existing providers(137). We demonstrate
continuous analysis on a user-defined “staging” branch. This enables researchers to
control costs by choosing when to trigger analyses that are automatically reproducible.
We strongly recommend the use of continuous analysis whenever a single machine can
be used. For workflows that require cluster computing, employing continuous analysis is
technically feasible but requires significant systems administration expertise because the
cluster must be provisioned automatically. For work involving cluster computing,
researchers may elect to employ continuous analysis for steps that do not require a
cluster. In this case, researchers should carefully report which steps in their workflows
the process covers. It is conceivable that continuous analysis systems could be
specifically designed for scientific workflows to facilitate reproducible cluster-based
analyses with the same ease as single-machine analyses.
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For small datasets and less intensive computational workflows it is easiest to use a
full service continuous integration service. These services have the shortest setup times –
often only requiring a user to enable the service and add a single file to their source code.
With private data or for analyses that include large datasets or require significant
computing, cloud-based or locally hosted continuous integration server can be employed.
Reproducibility could have wide-reaching benefits for the advancement of
science. For authors, reproducible work is credible. Stodden et al.(138) highlight the
importance of capturing and sharing data, software, and the computational environments.
Continuous analysis addresses reproducibility in this narrow sense by automatically
capturing the computational reagents needed to generate the same results from the same
inputs. It does not solve reproducibility in the broader sense: how robust results are to
parameter settings, starting conditions and partitions in the data. By automating narrowsense reproducibility, continuous analysis lays the groundwork needed to address
questions related to the reproducibility and robustness of findings in the broad sense.
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  Privacy-preserving generative deep neural networks support clinical
data sharing
4.3.1.   Abstract
Though it is widely recognized that data sharing enables faster scientific progress,
the sensible need to protect participant privacy hampers this practice in medicine. We
train deep neural networks that generate synthetic subjects closely resembling study
participants. Using the SPRINT trial as an example, we show that machine-learning
models built from simulated participants generalize to the original dataset. We
incorporate differential privacy, which offers strong guarantees on the likelihood that a
subject could be identified as a member of the trial. Investigators who have compiled a
dataset can use our method to provide a freely accessible public version that enables other
scientists to perform discovery-oriented analyses. Generated data can be released
alongside analytical code to enable fully reproducible workflows, even when privacy is a
concern. By addressing data sharing challenges, deep neural networks can facilitate the
rigorous and reproducible investigation of clinical datasets.
4.3.2.   Introduction
Sharing individual-level data from clinical studies remains challenging. The status
quo often requires scientists to establish a formal collaboration and execute extensive
data usage agreements before sharing data. These requirements slow or even prevent data
sharing between researchers in all but the closest collaborations.
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Recent initiatives have begun to address cultural challenges around data sharing. The
New England Journal of Medicine recently held the Systolic Blood Pressure Trial
(SPRINT) Data Analysis Challenge to examine possible benefits of clinical trial data
sharing (139, 140). The SPRINT clinical trial examined the efficacy of intensive
management of systolic blood pressure (<120 mmHg) compared with standard
management (<140 mmHg). Intensive management resulted in fewer cardiovascular
events and the trial was stopped early. Reanalysis of the challenge data led to the
development of personalized treatment scores (141) and decision support systems (142),
in addition to a more specific analysis of blood pressure management in participants with
chronic kidney disease (143). Such efforts have begun to address cultural norms. Even
for this effort which focused on data sharing, investigators were required to execute data
use agreements that included clauses to maintain security and prohibit re-identification or
sharing.
We sought to remove technical barriers that hamper data sharing. Computer
scientists have tackled problems considered to be particularly challenging using deep
neural networks (144). This class of machine learning methods is now becoming more
widely used in biology and medicine (145). In this work, we trained two deep neural
networks against each other to generate realistic simulated participant blood pressure
trajectories from the SPRINT trial dataset. One neural network, called the generator, is
trained to generate a participant from a set of random numbers. The other neural network,
called a discriminator, is trained to classify data as real or generated. As the networks are
trained, the generator learns to build samples that fool the discriminator. Networks
trained in this way are called Generative Adversarial Networks (GANs) (146) and can
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also be used for labeled samples (147). A pair of recent preprints have reported
participant generation via neural networks (148, 149). However, it is not enough to
simply build new examples. Numerous linkage and membership inference attacks have
demonstrated the ability to re-identify participants or reveal participation in a study on
both biomedical datasets (18, 150–155) and from machine learning models (19, 156,
157).
To provide a formal privacy guarantee, we build GANs under the constraint of
differential privacy (16). Informally, differential privacy requires that no subject in the
study has a significant influence on the information released by the algorithm (see
Materials and Methods for a formal definition). Despite being a stringent notion,
differential privacy allows us to generate new plausible individuals while revealing
almost nothing about any single study participant. This is especially important in the
biomedical domain where, for example, Homer et al. showed the ability to identify
whether an individual was a part of a study even with complex genomic mixtures (158).
Simmons and Berger later developed a method to enable differential privacy for genomewide association studies (159). Recently, methods have been developed to train deep
neural networks under differential privacy with formal assurances about privacy risks
(160, 161). In the context of a GAN, the discriminator is the only component that
accesses the real, private, data. By training the discriminator under differential privacy,
we can produce a differentially private GAN framework.
We evaluated whether or not this approach could generate biomedical data that could
be shared for reanalysis while reducing participant privacy risks. We evaluated usefulness
by: (1) comparing variable distributions between the real and simulated data, (2)
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comparing the correlation structure between variables in the real and simulated data, (3)
comparing machine learning predictors constructed on real vs. simulated data. We find
that the model learns realistic distributions and that models constructed from the
simulated data successfully classify participants in a held-out portion of the underlying
real dataset.
4.3.3.   Results
We used an Auxiliary Classifier Generative Adversarial Network (AC-GAN) (147)
to simulate participants based on the population of the SPRINT clinical trial. We
included all participants with measurements for the first twelve time periods (n=6,502);
dividing them into a training set (n=6,000) and a test set (n=502). We trained two ACGANs using the training set: a traditional, standard, AC-GAN (labeled non-private) and
an AC-GAN trained under differentially privacy (labeled private). We used both to
simulate data that we compared to the real data. We visualized participant blood pressure
trajectories, analyzed variable correlation structure and evaluated transfer learning
performance for a machine learning classification task.

4.3.3.1.  

Auxiliary Classifier GAN for SPRINT Clinical Trial Data.

An AC-GAN (Fig. 4.5 A) is made up of two neural networks competing with each
other. We found convolutional layers effectively modeled the sequential measurements
and used deep convolutional neural networks for both the generator and discriminator
(Fig. 4.5 B-C). We trained the Generator (G) to take in a specified treatment arm
(standard/intensive) and random noise and generate new participants that can fool the
Discriminator (D). We trained the discriminator to differentiate real and simulated data
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from a dataset containing both groups. We repeated this process until the generator
created synthetic participants that were difficult to discriminate from real ones.
We trained under differential privacy by limiting the effect any single subject has on
the training process and by adding random noise based on the maximum effect of a single
subject. From the technical perspective, we limited the effect of participants by clipping
the norm of the gradient and added proportionate Gaussian noise. This combination
offered plausible deniability, training could have been guided by a different subject
within or outside the real training data. The maximum effect of an outlier is limited and
bounded. Comparing the loss functions of the private and non-private training process
demonstrates the effects of these constraints. Under normal training the losses of the
generator and discriminator converged to an equilibrium before eventually increasing
steadily (Fig. 4.5 D). Under differentially private training the losses converged to and
remained in a noisy equilibrium (Fig. 4.5 F). At the beginning of training the neural
networks changed rapidly. As training continued and the model achieved a better fit these
steps, the gradient, decreased. When the gradient became very small, the noise
outweighed the signal and limited further training.
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Figure 4.5: AC-GAN architecture and training.
A.) Structure of an AC-GAN. B.) The generator model takes a class label and random noise as
input and outputs a 3x12 vector for each participant (SBP, DBP and medication counts at each
time point). C.) The discriminator model takes both real and simulated samples as input and
learns to predict the source and a class label (i.e. normal or intensive treatment group). D.)
Training loss for a non-private AC-GAN. E.) Training loss for a private AC-GAN.

4.3.3.2.  

Evaluation of Simulated Participants

After training the AC-GAN we compared the simulated synthetic participants to the
real participants (Figure 4.6). Figure 4.6 shows the median systolic blood pressures for:
(1) real participants, (2) simulated participants via a non-private AC-GAN and (3)
simulated participants via the differentially private AC-GAN. The non-private
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participants generated at the end of training appear similar to the real participants. The
private participants have wider variability because of the noise added during training
(Fig. 4.6 A). As the models achieve better fit, the gradient shrinks, causing the gradient to
noise ratio to decrease. This can occasionally lead to the private generator and
discriminator falling out of sync (Supp. Fig. 1) or more commonly the private model
generating less realistic samples. To best choose when to stop training, we developed an
approach that incorporates any machine learning analysis chosen to resemble expected
use cases. Here we tested each epoch’s data by training an additional classifier that must
distinguish whether a generated participant was a part of the normal or intensive
treatment groups. We applied two common machine learning classification algorithms
and selected the top epochs in a differentially private manner (Fig. 4.6 B and 4.6 C).
However, selecting only a single epoch does not account for the AC-GAN training
process. Because the discriminator and generator compete from epoch to epoch, their
results can cycle around the underlying distribution. The non-private models consistently
improved throughout training (Supp. Fig. 2A, Supp. Fig. 3A), but this could be due to the
generator eventually learning characteristics specific to individual participants. We
observed that epoch selection was important for the generation of realistic populations
from models that incorporated differential privacy (Supp. Fig. 2B, Supp. Fig. 3B). To
address this, we simulated 1,000 participants from each of the top five epochs by both the
logistic regression and random forest evaluation and combined them to form a multiepoch training set. This process maintained differential privacy and resulted in a
generated population that, throughout the trial, was consistent with the real population
(Fig. 4.6 D).
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Figure 4.6: Median Systolic Blood Pressure Trajectories from initial visit to 27 months.
A.) Simulated samples (private and non-private) generated from the final (500th) epoch of
training. B.) Simulated samples generated from the epoch with the best performing logistic
regression classifier. C.) Simulated samples from the epoch with the best performing random
forest classifier. D.) Simulated samples from the top five random forest classifier epochs and top
five logistic regression classifier epochs.

The Pearson correlation structure of the real data (Fig. 4.7 A) was closely reflected
by the correlation structure of the non-private
generated
Simulation
Results data (Fig. 4.7 B). Of note was
initial positive correlation between the number of medications a participant was taking

109

and the early systolic blood pressures, but this correlation decreased as time goes on. The
private generated data generally reflects these trends, but has an increased level of noise
(Fig. 4.7 C). The noisy training process of the private discriminator places an upper
bound on its ability to fit the distribution of data. Increased sample sizes would help to
clarify this distribution and because larger sample sizes cause less privacy loss, less noise
would need to be added to achieve an acceptable privacy budget.
A.

B.

C.

Figure 4.7: Correlation structure between variables in the data.
Pairwise Pearson correlation between columns for the A.) Original, real data, B.) Non-private,
AC-GAN simulated data C.) Differentially private, AC-GAN simulated data.

Feasibility of Simulated Participants for Transfer Learning Task
Visualizations of patient distributions and variable correlations showed that synthetic
participants appeared similar to real participants. We sought to determine whether or not
synthetic participants could be used for subsequent data mining. We trained machine
learning classifiers using four methods (logistic regression, random forests, support
110

vector machines, and nearest neighbors) to distinguish treatment groups on three different
sources of data: real participants, synthetic participants generated by the non-private
model, and synthetic participants generated by the private model. We compared
performance of these classifiers on a holdout test set of 502 real participants (Fig. 4.8 AD). This analysis revealed two main trends: classifiers trained on the set constructed from
combined top epochs exhibited more stable performance on the test data in line with
observations from the population distributions, and classifiers trained on data from the
non-private model slightly outperformed those trained on data from the private model. A
drop in performance was expected because adding noise to maintain privacy reduces
signal. If desired, training a non-private model could provide an upper bound for
expected performance.
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Figure 4.8: Performance and Variable importance in a transfer learning task.
A.) Performance on transfer learning task by source of training data for each machine learning
model. B.) Random forest variable importance scores by training data. C.) Logistic Regression
variable coefficients by training data. D.) Support Vector Machine variable coefficients by
training data.
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We also sought to determine the extent to which the classifiers were using similar
predictive features. We evaluated the random forest feature importance scores (Fig. 4.8
E) as well as the logistic regression and support vector machine feature coefficients (Fig.
4.8 G, F). All showed similar trends of useful features between real and generated data,
and a spearman correlation test was performed between the importance scores (random
forest) and coefficients (SVM and logistic regression) of the models trained on real data
and each synthetic set revealed significant associations in all cases (Table 4.1). Though
all three classification methods achieved similar accuracy, the random forest classifier
found the medication features to be important while these features had near zero
coefficients in the SVM and logistic regression classifiers.
Random Forest
Real - NonPrivate
Real - Private

Correlation
0.6761
0.6787

P-Value
5.998e06
5.357e06

Support Vector
Machine
Correlation
P-Value
0.7266
5.2284e-07
0.7462

1.7493e-07

Logistic
Regression
Correlation P-Value
0.6687
8.2723e06
0.5425
0.00062

Table 4.1: Spearman Correlation between variable importance scores (Random Forests) and
model coefficients (Support Vector Machine and Logistic Regression).

4.3.3.3.  

Privacy Analysis

The formal definition of differential privacy has two parameters. The key parameter
ε measures the “privacy loss” incurred by the computation. The second parameter δ
bounds the probability that the privacy loss exceeds ε. The values of (ε, δ) accumulate as
the algorithm repeatedly accesses the private data. In our experiment, our private ACGAN algorithm is able to generate useful synthetic data with ε = 2 and δ < 10^{-5}
(Figure 4.9). The upper bound of the epoch selection task, (see Materials Methods) used
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(0.05, 0) per each model included for a total of (0.5, 0) differential privacy. This
established a modest, single digit epsilon privacy budget of (2.5, 10-5).

Figure 4.9: Privacy Parameter values during training.
The value of delta as a function of epoch for different epsilon values. An ε value of 2 allows for
500 epochs of training and δ < 10-5.

4.3.4.   Discussion
Deep generative adversarial networks and differential privacy offer a technical
solution to the challenge of sharing biomedical data to facilitate exploratory analyses.
Our approach, which uses deep neural networks for data simulation, can generate
synthetic data to be distributed and used for secondary analysis. We perform training with
a differential privacy framework that limits the study subjects’ privacy risk. We apply
this approach to data from the SPRINT clinical trial due to its recent use for a data
reanalysis challenge
We introduce an approach that samples from multiple epochs to improve
performance while maintaining privacy. However, several challenges remain. Deep
learning models have many training parameters and require substantial sample sizes,
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which can hamper this method’s use for small clinical trials or targeted studies. Another
fruitful area of use may be large electronic health records systems, where the ability to
share synthetic data may aid methods development and the initial discovery of predictive
models. Similarly, financial institutions or other organizations that use outside contractors
or consultants to develop risk models might choose to share generated data instead of
actual client data. In very large datasets, there is evidence that differential privacy may
even prevent overfitting to reduce the error of subsequent predictions (162).
Though our approach provides a general framing, the precise neural network
architecture may need to be tuned for specific use cases. Data with multiple types
presents a challenge. EHRs contain binary, categorical, ordinal and continuous data.
Neural networks require these types to be encoded and normalized, a process that can
reduce signal and increase the dimensionality of data. New neural network have been
designed to deal more effectively with discrete data (163, 164). Researchers will need to
incorporate these techniques and develop new methods for mixed types if their use case
requires it. The practice of generating data under differential privacy with deep neural
networks offers a technical solution for those who wish to share data to the challenge of
patient privacy. This technical work complements ongoing efforts to change the data
sharing culture of clinical research.
4.3.5.   Materials and Methods
We developed an approach to train auxiliary classifier generative adversarial
networks (AC-GANs) in a differentially private manner to enable privacy preserving data
sharing. Generative adversarial networks offer the ability to simulate realistic-looking
data that closely matches the distribution of the source data.
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AC-GANs add the ability to generate labeled samples. By training AC-GANs under
the differential privacy framework we generated realistic samples that can be used for
initial analysis while guaranteeing a specified level of participant privacy.
The source code for all analyses is available under a permissive open source license
in our repository (https://github.com/greenelab/SPRINT_gan). In addition, continuous
analysis (22) was used to re-run all analyses, to generate docker images matching the
environment of the original analysis, and to track intermediate results and logs. These
artifacts are freely available (https://hub.docker.com/r/brettbj/sprint-gan/ and archival
version: https://doi.org/10.6084/m9.figshare.5165731.v1).
4.3.5.1.  

SPRINT Clinical Trial Data

The SPRINT was a randomized, single blind treatment trial where participants were
randomized into two groups, an intensive treatment group with a systolic blood-pressure
target of less than 120 mmHg and a standard treatment group with a systolic bloodpressure target of less than 140 mm Hg. The trial included a total of 9,361 participants.
We included 6,502 participants from the trial by filtering for all participants that had
blood pressure measurements for each of the first 12 measurements (RZ, 1M, 2M, 3M,
6M, 9M, 12M, 15M, 18M, 21M, 24M, 27M). We included measurements for systolic
blood pressure, diastolic blood pressure and the count of medications prescribed to each
participant. This provided an input vector of shape (3, 12).
4.3.5.2.  

Auxiliary Classifier Generative Adversarial Network

We implemented the AC-GAN as described in Odena et al. (147) using Keras (89).
Results shown use a latent vector of dimension 100, a learning rate of 0.0002, and a batch
size of 100. To handle edge cases and mimic the sensitivity of the real data
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measurements, we take the floor of zero or the simulated value and convert all values to
integers.
4.3.5.3.  

Transfer Learning Task

Each of the 6,502 in the SPRINT dataset is labeled by their treatment group. We
evaluate machine learning methods (logistic regression, support vector machines, and
random forests from the scikit-learn (56) package) by their ability to predict which group
a participant belongs to. This was done by splitting the 6,502 into a training set of 6,000
participants (labeled real) and a test set of 502 participants. A vanilla AC-GAN was
trained using the 6,000 participant training set providing a simulated training set (labeled
non-private). A differentially private AC-GAN was trained using the 6,000 training set
providing a differentially private training simulated training set (labeled private). Each
classifier was then trained on the real, non-private and private training sets and evaluated
on the same, real test set of participants. This allows for a comparison of classification
performance between models trained on the real data, synthetic data and private synthetic
data. We evaluated both accuracy as well as the correlation between important features
(random forest) and model coefficients (logistic regression and support vector machine).
4.3.5.4.  

Differential Privacy

Differential privacy is a stability property for algorithms, specifically for randomized
algorithms (165). Informally, it requires that the change of any single data point in the
data set has little influence on the output distribution by the algorithm. To formally define
differential privacy, let us consider X as the set of all possible data records in our domain.
A dataset is a collection of n data records from X. A pair of datasets D and D’ are
neighboring if they differ by at most one data record. In the following, we will write R to
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denote the output range of the algorithm, which in our case correspond to the set of
generative models.

Definition 1 [Differential Privacy (166)]: Let ε, δ > 0. An algorithm A: Xn → R satisfies
(ε, δ)-differential privacy if for any pair of neighboring datasets D, D’, and any event S
⊆ R, the following holds
Pr[A(D) ∈ S ] ≤ Pr[A(D’) ∈ S ] exp(ε) + δ,
where the probability is taken over the randomness of the algorithm.

A crucial property of differential privacy is its resilience to post-processing --- any
data independent post-processing procedure on the output by a private algorithm remains
private. More formally:
Lemma [Resilience to Post-Processing]: Let algorithm A: Xn → R be an (ε, δ)differentially private algorithm. Let A’ : R → R’ be a “post-processing” procedure. Then
their composition of running A over the dataset D, and then running A’ over the output
A(D) also satisfies (ε, δ)-differential privacy.

4.3.5.5.  

Training AC-GANs in a Differentially Private Manner

During the training of AC-GAN, the only part that requires direct access to the
private (real) data is the training of the discriminator. To achieve differential privacy, we
only need to “privatize” the training of the discriminators. The differential privacy
guarantee of the entire AC-GAN directly follows because the output generative models
are simply post-processing from the discriminator.
To train the discriminator under differential privacy we add noise to the stochastic
gradient descent process as outlined in Abadi et al. (160). First, we provide an upper
bound onto the norm of the gradient at any individual step. This is done by clipping the
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ℓ2-norm of the gradient. Next, we perturb each coordinate of the gradient by adding noise
drawn from a Gaussian distribution with a variance proportional to the gradient clipping.
The more noise we added (relative to the clipped norm of the gradient) the better privacy
guarantee. To achieve a modest privacy budget, we found we could clip the ℓ2-norm of
the gradient at 0.0001 and add noise from a normal distribution with a σ2 of 1 (Ɲ(µ, 1 *
(0.00012))). This is substantially higher than previously shown, likely due to either the
dynamic nature of GAN training where the target is inexact and changes over time or
averaging over many mini-batches. We used the moments accountant described in Abadi
et al. (160) to compute the privacy parameters (ε, δ).
4.3.5.6.  

Differentially Private Model Selection

We found that sampling from multiple different epochs throughout training provided
a more diverse training set. This provided summary statistics closer to the real data and
higher accuracy in the transfer learning task. During the GAN training, we saved all the
generative models across all epochs. We then generated a batch of synthetic data from
each generative model, and used a machine learning algorithm (logistic regression or
random forest) to train a prediction model based on each synthetic batch of data. We then
tested each prediction model on the real dataset and calculate the resulting accuracy. To
select epochs that generate training data for the most accurate models under differential
privacy, we used the standard “Report Noisy Min” subroutine: first add independent
Laplace noise to the accuracy of each model (drawn from Lab(1/(n*ε)) to achieve (ε, 0)
differential privacy where n is the size of the private dataset we perform prediction on
and output the model with the best noisy accuracy.
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In practice, we choose the top five models in the transfer learning task using both
logistic regression classification and random forest classification (for a total of 10
models). We performed this task under (0.5, 0)-differential privacy. In each of the ten
rounds of selection epsilon was set to 0.05. This achieves a good balance of accuracy
while maintaining a reasonable privacy budget.
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  Abstract
Electronic Health Records (EHRs) contain a wealth of patient data useful to
biomedical researchers. At present, both the extraction of data and methods for analyses
are frequently designed to work with a single snapshot of a patient’s record. Health care
providers often perform and record actions in small batches over time. By extracting
these care events, a sequence can be formed providing a trajectory for a patient’s
interactions with the health care system. These care events also offer a basic heuristic for
the level of attention a patient receives from health care providers. We show that is
possible to learn meaningful embeddings from these care events using two deep learning
techniques, unsupervised autoencoders and long short-term memory networks. We
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compare these methods to traditional machine learning methods which require a point in
time snapshot to be extracted from an EHR.

  Introduction
After the U.S. government mandated meaningful use of electronic health records
(EHRs) by 2014, they have been widely adopted with 96% of health care providers
implementing an EHR (167). Patient interactions with the health care system are recorded
in the EHR. Many research analyses treat the EHR as a static document by taking a
snapshot of a patient`s EHR and using this for downstream analyses. This fails to account
for the way a patient changes over time, their trajectory.
Jensen et al. (24) proposed the idea of temporal disease trajectories to model
expected progression for a patient over time. This study uses billing codes as disease
labels, which may introduce biases inherent to the billing process. Patients may be
assigned a billing code before being diagnosed for a disease in order to receive a
diagnostic test. Billing codes place also binary rules on the presence of disease. Perhaps
most importantly for this work billing codes are frequently assigned after a visit and are
thus not helpful for tracking patient trajectories over the course of an inpatient admission
or rapid series of visits.
Interactions between patients and the health care system tend to occur in bursts,
related to a specific visit or a series of visits. We label these periods of activity as care
events and group these actions together. These care events represent changes over time
and can capture longitudinal changes of a patient`s state.
Denny et al. (168) first showed the ability to use autoencoders to model clinical
measures in an unsupervised manner. More recently, several groups have used
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autoencoders to learn high level features useful for classification (91, 169) and
imputation (170). Tan et al. also showed the ability to extract meaningful features from
gene expression data using autoencoders (26). We use autoencoders to represent patient
care events in a low dimensional vector space that is useful for visualization. Positions in
this vector space represent the patient`s condition at a point in time. By connecting these
positions, or care events, in order, it is possible to see how a patient`s condition changes
over time and how they move through the health system. It is also possible to cluster
patients in this low dimensional space and examine when patient outcomes diverge, one
group having high survival and the other having high mortality.
This care event representation also provides a natural sequence of events. Recurrent
neural networks have shown an impressive ability to model sequences to solve problems
in many domains including object recognition in computer vision (171), image (172) and
text generation (173). Long short-term memory networks (LSTMs) (174) are a type of
recurrent neural network that have recently been applied to clinical data to learn low
dimension representations of medical concepts (175) and to make classifications using
time series of specific clinical measures (176, 177).
Trajectories have been used to model multistage dynamic decision processes (DMP)
in discrete optimization problems (178). In Algebraic Logical Meta-Model (ALMM) the
state of the system in a certain time depends on the previous state, undertaken decision
and transition function. This concept allows to easily describe the state of the patient at a
particular time, with specific actions taken (e.g. application of medication) to manage the
response to previous events within the progression of a disease.
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In this work, we first demonstrate that deep learning approaches can (1) learn patient
embeddings useful for both interpretable expert analysis via visualization and (2) do this
we use the Medical Information Mart for Intensive Care III (MIMIC) database and apply
both unsupervised deep autoencoders and LSTMs.

  Methods
5.3.1.   Source Code and Analysis Availability
Source code to reproduce the analyses in this work are provided in our repository
(https://github.com/EpistasisLab/MIMIC_trajectories) under a permissive open source
license. In addition, Continuous Analysis (22) was used to generate docker images
matching the environment of the original analysis.

  Care Event Extraction
5.4.1.   Medical Information Mart for Intensive Care III (MIMIC) Critical Care
Database
MIMIC (179) is a publicly available database composed of 46,297 critical care deidentified electronic health records for patients at Beth Israel Deaconess Medical Center.
It includes all charted data (demographics, vital signs, medications, procedures,
diagnoses, patient outputs, laboratory tests, physician notes, and treatment details) for
patients from 2001 to 2012.
5.4.2.   Extracting Care Events from MIMIC
We divided the MIMIC database into 4 groups:
1.   Static data that does not change over the course of an admission (i.e. demographic data).
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2.   Actions performed by health care providers that have a specific time associated with
them (i.e. laboratory events).
3.   Actions performed by health care providers that only have a date associated with them
(i.e. oral medications).
4.   Streaming data measured on a per-minute basis (i.e. heart rate).

Category (MIMIC Database Table)

Example

DATETIMEEVENT
ICUSTAYS
INPUTEVENTS_CV &
INPUTEVENTS_MV

Changing equipment or standard repeated treatments (i.e. dialysis).
Transfer to or from the Intensive Care Unit.
Any fluids given to the patient (i.e. an IV solution, CV and MV stand for
the two systems used to track these events Philips Carevue and iMDSoft
Metavision).
All lab measurements for a patient (i.e. Creatinine level).
All procedures performed on a patient (i.e. Extubation).
Changes in which service a patient is under (i.e. Cardiac Surgery)

LABEVENTS
PROCEDUREEVENTS
SERVICES

Table 5.1: Categories and examples of Care Event Actions.

To define care events, we included all actions initiated, or charted, by health care
providers that have a specific time associated with them (Table 5.1). These actions were
placed in sequential order and grouped together until there was a gap greater than the
margin time (Figure 5.1). Because this is critical care data, the timeline between events is
much smaller than typical EHR data. We found a 59 minute margin time yielded care
events that had a good balance of inclusiveness while not including extended time
periods. This yielded 1,566,026 total care events and an average of 26.80 care events per
admission. In non-critical care datasets, we expect a margin time of several days may
better capture the concept of a care event.
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Figure 5.1: Example of care event extraction.
Example of care event extraction. Green circles indicate actions taken by health care providers.
Lines and numbers below indicate care events.

5.4.3.   Stratification of Patient Attention based on type of Insurance Provider
Care events can provide a useful heuristic to the level of interaction between the
health care provider and a patient. To evaluate attention, we compared the time spent in
the hospital per admission with the number of care events per admission and the average
number of care events per day. We then performed Welch’s t-test between patients with
private insurance and each of the other types of insurance (Medicare, Medicaid,
Government, Self-Payment) to see if there were significant differences between patients
with differing insurance types.

  Unsupervised learning to learn embeddings of extracted Care Events
5.5.1.   Applying Autoencoders to Extracted Care Events to cluster in a low
dimensional space.
We used the Keras library (89) to construct autoencoders with 7 hidden layers in
(1196, 512, 256, 128, 64, 128, 256, and 512 nodes per layer). We used dropout to mask
20% of the connections between the input layer and the first hidden layer. The model was
trained using binary cross entropy loss with Adam (180). The middle, hidden layer (64
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nodes) was used as an output for visualization using t-Stochastic Neighbor Embedding
(58). The resulting visualizations were labeled for enrichment of 1-year patient survival.
5.5.2.   Predicting Survival Using Care Events
We evaluated how effectively different machine learning methods could predict
patient survival throughout the course of the critical care visit, a 6-month period and a 1year period (as measured from the original admission date). For this analysis, we
performed 5-fold cross validation providing a training set of 46,751 admissions and a test
set of 11,687 admissions chosen via stratified cross validation (56). Survival was
predicted using a standard feed forward or multi-layer perceptron deep neural network
(89), a random forest, logistic regression and support vector machine (56) after various
numbers (N) of care events: 1, 3, 5, 10, 20, 30 and 50. Area under the curve of the
receiver operating characteristic was used for evaluation and comparison between
methods.
5.5.3.   Traditional machine learning methods to predict survival from an EHR
Snapshot.
To build a snapshot vector useable for traditional machine learning methods. We
took the mean of each value from a set of care events, up to the Nth care event. If the
patient had less than N care events, we took the mean for all of their care events. This
aggregate vector was provided as input to each of the machine learning classifiers.
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5.5.4.   Long Short Term Memory Networks (LSTMs) to predict survival with Care
Events Sequences.
To build the sequence vector from a set of care events we first truncated sequences
longer than N. Sequences shorter than N were post-padded with zeros. The model was
comprised of 3 types of layers, an initial embedding layer, three LSTM layers (with 100,
50 and 50 nodes respectively) and a fully connected (Dense) output layer. We trained the
model using rmsprop (181) with a binary cross entropy loss function.

  Results
The MIMIC dataset includes 58,438 admissions from 46,297 unique patients. This was
extracted to form 1,566,026 care events (Table 5.2). Medicare patients were double the age
of other patients on average. Patients using private or government insurance and Medicaid
had relatively equal mortalities during the initial admission and the next 6 months. Patients
using Medicare had significantly higher mortality in the 6 months after admission as their
time under critical care and self-payment patients had high mortality during the admission
but lower admission after leaving critical care.
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5.6.1.   Treatment and Outcome Comparison

Patients
Admissions
Admissions
per Patient
Average Age
at Admission
Care Events
Care Events
per
Admission
Visit
Survival
6-Month
Survival
12-Month
Survival

Total

Male

Female

Private

Medicare

Medicaid

Government Self

46,297
58,438
1.26

26,121
32,950
1.26

20,399
26,026
1.28

19,663
22,250
1.13

21,002
28,103
1.34

4,570
5,713
1.25

1,614
1,767
1.09

600
605
1.01

56.01

54.95

57.34

37.82

75.95

37.91

35.15

39.11

1,566,026
26.80

867,941
26.34

698,085
26.82

637,968
28.67

693,254
24.67

179,182
31.36

46,722
26.44

8,900
14.71

90.84%

90.38%

89.56%

95.24%

86.40%

94.60%

95.87%

85.2%

79.81%

79.63%

78.39%

89.84%

69.47%

87.61%

91.62%

83.31%

76.28%

76.19%

74.82%

87.90%

64.33%

84.75%

90.32%

82.81%

Table 5.2: Summary statistics for MIMIC Critical Care database.

We examined the length of stay per admission by insurance type (Figure 5.2 A) and
found that patients using Medicare had the longest stays but that all groups differed
significantly via a Welch’s t-test from patients using private insurance. It is not surprising
that patients using self-payment had the shortest stays and the least number of care events
per stay (Figure 5.2 A-C). Interestingly, patients with private insurance had significantly
lower care events per day than the most similar other groups, government-based
insurance and Medicaid (Figure 5.2 C).
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Figure 5.2: Association testing between different insurance types.
A.) Length of admission. B.) Number of care events in an admission. C.) Number of care events
per day of each admission. Labels at the top indicate p-values via Welch’s t-test to private group.

5.6.2.   Unsupervised modeling of patient Care Events
To test whether unsupervised autoencoders could learn meaningful embeddings from
individual care events, we plotted the innermost hidden layer using t-Stochastic Neighbor
Embedding (t-SNE) and overlaid 1-year survival labels (Figure 5.3). This process yielded
several clusters with high enrichment for either mortality or survival indicating the ability
to learn meaningful embeddings. t-SNE does not maintain global similarity structure and
as such this process is useful for visualizing single care events but not for understanding
patient trajectories. In order to examine patient trajectories, it is necessary to look at the
value of the innermost hidden layer before t-SNE was applied or to use a method
designed to model sequential data. Recurrent neural networks, and specifically LSTMs
are well suited at this task.
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Figure 5.3: Unsupervised Care Events Embedding Visualization.
Performed by applying t-SNE to the innermost layer of autoencoder (1000 care events shown to
prevent overplotting).

5.6.3.   Supervised prediction of patient survival
Next, we preformed the supervised classification task of predicting whether a patient
survived one full year from the date of their admission. We measured classification
accuracy with differing numbers of care events to evaluate whether the care event based
approach had advantages over traditional single point in time measurements (Figure 5.4).
Of the methods predicting based on a snapshot, the random forest was by far the most
effective. Despite this, it did not increase in performance as more information about an
admission was added. This indicates that much of it’s predictive power comes from the
initial presentation. Both, linear methods and a traditional feed-forward neural network
barely outperformed random chance. This may have been due to the high dimensionality
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of the dataset. The care event-based LSTM increases in performance as more care events
are provided. This is particularly evident when more than the median number of care events
(26.8) are provided as input to the LSTM. Including more than 50 care events yielded
weaker results for the LSTM. This is likely because most patients have fewer than 50 care
events so most of the signal is captured in the first 50 care events. Going beyond 50 leads
to a high level of padding to signal.

Figure 5.4: Predicting Survival with Care Event Approach.
Comparison of machine learning methods and the number of care events provided for 1-year
survival prediction (AUROC).

  Discussion and Conclusions
By limiting the usage of summary statistics to small time periods, we offer a granular
method for modeling longitudinal clinical data. The care event extraction method
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provides a simple data driven approach to extracting temporal data for use in time series
analyses. It allows summary statistics to be computed over short time windows as
opposed to an entire patient history or arbitrary timestamps. Care events also offer a
heuristic to allow comparison of the level of attention different patients receive from
health care providers. We demonstrated the ability to learn embeddings enriched for
different endpoints using unsupervised deep learning and were able to more accurately
predict patient survival using supervised long short-term memory networks.
Though our approach showed strong performance for several tasks in this dataset,
this method currently has limitations in terms of generalization. Long-short term memory
networks, like many deep learning approaches, require many patients to outperform other
methods. This can present a challenge when studying a single phenotype instead of a
wide variety of critical care patients. The greatest benefits are likely to be seen when
patients have many care events, making this approach particularly well suited for chronic
diseases like type 2 diabetes and Crohn’s disease or for diseases that are hard to subtype
such as multiple sclerosis. An additional challenge is if a patient with a disease like type
2 diabetes suffers an unrelated acute injury (i.e. broken rib in a vehicle accident) this
acute injury may introduce too much noise to capture the type 2 diabetes trajectory. In
future work, we hope to introduce filtering techniques to exclude or deemphasize
unrelated diagnoses.
We also plan to increase the dimensionality of the encoders and applying additional
techniques of visual clustering (182). This includes using Shared-Nearest Neighbors
(SNN) clustering to find groups of patients with similar stage of the disease in noisy data
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and Mukres algorithm to map groups of patients resembling a state of the disease to
clusters found in the data.
Another challenge we would like to take is including streaming data in the
simulation. Some measurements, e.g. heart rate or blood pressure, are performed every
minute for each patient. The information about sudden changes of patient’s condition is
especially relevant for intensive-care patients. While our method aggregates patient data
over shorter time periods than are commonly used, we plan to adapt our model by adding
more detailed relevant information extracted from streaming sources.
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Chapter 6.  

Summary and Future Directions

The ability to more precisely define diseases, extract phenotypes and advise data
driven treatment strategies are just a few of the wide array of the possibilities enabled by
the wealth of data contained in EHRs. We aim to provide machine learning methods to
address the barriers slowing or preventing progress at these tasks. Semi-supervised
learning can be used to compensate for the lack of research quality labels available in
EHRs. Smart imputation strategies can infer missing values while minimizing impact on
downstream analyses. Continuous analysis can synchronize code to figures and enable
reproducible research even when working with private data. Adversarial training of deep
neural networks can be used to generate synthetic patient populations while preserving
privacy and discretization of care combined with recurrent neural networks can model
patient trajectories over time. This work takes steps towards solving these barriers which
we hope enables new possibilities and raises several new questions around the usage of
machine learning for both academic research and predictive analytics in patient care.
Despite our progress, there are significant limitations to our approaches and further work
will need to be done to completely solve these challenges. This section identifies these
limitations and challenges as well as speculates at promising opportunities using machine
learning in the EHR over the next several years.
Machine learning in the EHR requires pre-processing and imputation (Chapter 2 &
Chapter 3), but best practices in these field currently require an ad hoc implementation
followed by analyses to measure how robust results are to differences in pre-processing
and imputation. We demonstrated the ability to create a synthetic patient population using
GANs (Chapter 4) in a well-controlled structured clinical trial. Generalizing this task

135

presents several difficult challenges. GANs currently are not effective at generating
mixed data types (continuous, ordinal, categorical, etc.). In addition, they require large
sample sizes to effectively model a distribution. Training GANs under differential
privacy has not yet been shown possible for high dimensional data that is common in
biomedical data (i.e. genotypes). Overcoming these challenges will require significant
technical adjustments and potentially a reformulation of the problem. Challenges in
generalizing the longitudinal analysis (Chapter 5) largely based on two things, 1.)
variable times between care events that become more significant outside of the critical
care environment, and 2.) the potential of a recurrent neural network to learn from
padding, that is to learn form the number of care events rather than the contents of those
events. These issues were reduced in the critical care setting because there was a lower
variance in the time between care events than there would be in a traditional setting and
there was not a correlation between the number of care events and survival.
Traditionally, genetic association studies relied on binary outcomes as target
phenotypes for the association. Quantitative trait loci studies provide the ability to
measure correlation between DNA variation and a phenotype. Quantitative traits occur on
a continuum and are driven by multiple genes in conjunction with the environment. By
using clustering and other machine learning techniques, researchers can represent disease
as quantitative rather than binary values. This has several advantages. Patients with a
common disease that present with different symptoms, different levels of effect or
different paths of progression can be clustered into homogenous subgroups with similar
patients. These clusters are likely enriched etiologically, meaning the reasons the disease
is causing each cluster are different. Within each cluster or across the entire spectrum of
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diseases, a phenotype can be constructed to better represent how severe of a case a patient
has. Diseases where using a binary case control status has been effective are likely
etiological homogenous, or so disruptive to a particular system that the severity is
irrelevant. These represent the low hanging fruit, but many diseases present in
heterogeneous manners (Cancers, Amyotrophic Lateral Sclerosis, Multiple Sclerosis,
Alzheimers etc.). Fine-tuned quantitative phenotyping could have the ability to resolve
homogenous subgroups, greatly increasing statistical power and creating a better target
for association.
Deep Learning has already led to state of the art results in a variety of fields
including image processing, speech recognition, and gameplay. Many of the early “wins”
using deep learning and more generally machine learning in the EHR involve
applications of algorithms proven successful in other domains. This has been particularly
true in unstructured EHR data such as images (cancer tumor detection etc.) and natural
language processing for free text. This is sufficient when EHR learning tasks resemble
tasks that are already popular among general machine learning researchers. Within
biomedical informatics, this is the low hanging fruit. Long term advances will require
specialized solutions designed specifically for the unique challenges presented by EHRbased research. Algorithmic development is only one part of the equation. The proper
phrasing of problems and preprocessing of data will likely have as much if not more
importance than algorithmic development.
Three of the pioneers of deep learning, Yann Lecun, Yoshua Bengio and Geoffrey
Hinton wrote, “Unsupervised learning had a catalytic effect in reviving interest in deep
learning, but has since been overshadowed by the successes of purely supervised
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learning… we expect unsupervised learning to become far more important in the longer
term” (183). The challenge of collecting labeled data for supervised learning in the EHR
may be an ideal environment for a reemergence of unsupervised and semi-supervised
learning approaches. Early examples show that deep autoencoders are adept at this task
(91, 169).
For some clinical decisions, a black box algorithm with high accuracy is sufficient to
improve medical care. An algorithm that can more accurately identify a tumor in imaging
than a human has obvious benefits. For other problems, a black box is insufficient, it is
unlikely to help researchers understand the physiology or etiology of a disease. In this
setting, outside of a clinical decision, a less accurate but interpretable algorithm may be
preferred. In addition, clinicians are likely to be skeptical and slower to adopt algorithms
whose decisions cannot be rationally explained.
Furthermore, in April 2016, the European Union passed a data protection law
entitled the “General Data Protection Regulation (GDPR) which will begin in 2018. The
GDPR provides stricter conditions for sensitive data collection and storage, including, for
example genetic and biometric data. It also sets regulation on privacy policies and further
formalizes the “right to be forgotten.” Of particular interest to the machine learning
community is the language prohibiting decisions “based solely on automated processing
and which produces adverse legal effects concerning, or significantly affects, him or her”
and provides the right “to obtain an explanation of the decision reached after such
assessment or to challenge the decision.” It remains to be seen how this would be applied
and if it will have any effect on the usage of artificial intelligence in the clinic but it
demonstrates the fact that people want to understand how and why a decision affecting
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their wellbeing is made. Work to create high performing algorithms that provide
interpretable, explainable decisions is increasingly important as clinicians begin to rely
on the aid of artificial intelligence.
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